var title_f4_39_4720="Mammary line";
var content_f4_39_4720=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61921&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61921&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Location of accessory nipples",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 454px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Location of accessory nipples (blue line, mammary line).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sadler T, PhD. Langman's Medical Embryology, Ninth Edition Image Bank. Baltimore: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy;2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_39_4720=[""].join("\n");
var outline_f4_39_4720=null;
var title_f4_39_4721="Liver biopsy";
var content_f4_39_4721=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Liver biopsy (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?4/39/4721/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/39/4721/contributors\" id=\"au6409\">",
"       Sanjiv Chopra, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?4/39/4721/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/39/4721/contributors\" id=\"se8782\">",
"       Keith D Lindor, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?4/39/4721/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/39/4721/contributors\" id=\"de2797\">",
"       Anne C Travis, MD, MSc, FACG",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?4/39/4721?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      LIVER BIOPSY OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     The liver is a large organ that is located in the right upper abdomen beneath the rib cage (",
"     <a class=\"graphic graphic_figure graphicRef64960 \" href=\"UTD.htm?39/54/40804\">",
"      figure 1",
"     </a>",
"     ). It performs many functions that are essential to life.",
"    </p>",
"    <p>",
"     A liver biopsy is a procedure that involves obtaining a small piece of liver tissue, which is then analyzed in the laboratory. Liver biopsy may be recommended to diagnose a problem or determine the severity of liver disease. The most common reason to obtain a liver biopsy is to determine if there is scar tissue in the liver (and if there is, how much) in a person with chronic liver disease.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      REASONS FOR LIVER BIOPSY",
"     </span>",
"    </p>",
"    <p>",
"     As a general rule, a liver biopsy is recommended only when the results would affect your treatment or management. Some of the more common reasons for liver biopsy include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Non-alcoholic fatty liver disease (NAFLD) &mdash; NAFLD is a condition in which there are increased amounts of fat in the liver. NAFLD is the most common reason for liver biopsy. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?11/47/12018?source=see_link\">",
"        \"Patient information: Nonalcoholic steatohepatitis (NASH) (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Certain liver diseases, such as chronic hepatitis B or C, primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis, hemochromatosis or Wilson's disease. A biopsy can provide information about how severely the liver is damaged. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?30/45/31447?source=see_link\">",
"        \"Patient information: Hepatitis B (Beyond the Basics)\"",
"       </a>",
"       and",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?17/4/17478?source=see_link\">",
"        \"Patient information: Hepatitis C (Beyond the Basics)\"",
"       </a>",
"       and",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?2/41/2709?source=see_link\">",
"        \"Patient information: Hemochromatosis (hereditary iron overload) (Beyond the Basics)\"",
"       </a>",
"       and",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?24/56/25474?source=see_link\">",
"        \"Patient information: Autoimmune hepatitis (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Unexplained liver disease or abnormal liver function tests (blood tests that reflect injury to the liver).",
"      </li>",
"      <li>",
"       Evaluation of a mass seen on an imaging test like an ultrasound, computed tomographic (\"CAT\") scan, or MRI.",
"      </li>",
"      <li>",
"       Monitoring the liver following a liver transplant.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     A liver biopsy may also be helpful in people with unexplained fevers, those with certain rare metabolic diseases, and other less common disorders.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      LIVER BIOPSY PREPARATIONS",
"     </span>",
"    </p>",
"    <p>",
"     Prior to a liver biopsy, a healthcare provider will check blood tests that reflect how well your blood clots. Normal blood clotting is important to prevent bleeding after the biopsy.",
"    </p>",
"    <p>",
"     You should carry a list of your medications, including over-the-counter medications, herbs, and vitamins. Discuss this list with your clinician before the biopsy to see if you need to stop any medications temporarily.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Medications to avoid before liver biopsy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Patients are usually advised",
"     <strong>",
"      not",
"     </strong>",
"     to take medications that can increase the risk of bleeding. These include the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Aspirin or aspirin-containing medicines.",
"      </li>",
"      <li>",
"       Other nonsteroidal antiinflammatory drugs (NSAIDS) such as ibuprofen (eg, Motrin&reg;, Advil&reg;), and naproxen (eg, Aleve&reg;). Many non-prescription medicines contain NSAIDs, so check the labels or ask your pharmacist for help.",
"      </li>",
"      <li>",
"       Medicines used to prevent blood clots, such as warfarin (Coumadin&reg;).",
"      </li>",
"      <li>",
"       Certain medicines for heart conditions (such as abciximab [Reopro&reg;], dipyridamole [Persantine&reg;], ticlopidine [Ticlid&reg;], and clopidogrel [Plavix&reg;]).",
"      </li>",
"      <li>",
"       Some herbal therapies (such as fish oil or ginkgo biloba).",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Testing before liver biopsy",
"     </span>",
"     &nbsp;&mdash;&nbsp;It is common to have an ultrasound of the liver and gallbladder area before the biopsy so that your doctor can pinpoint the biopsy site. Ultrasounds are not required in every case; the need for ultrasound will be determined by the doctor who does the biopsy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Eating before liver biopsy",
"     </span>",
"     &nbsp;&mdash;&nbsp;You should have nothing to eat or drink for six hours before the procedure. You may be allowed to have a light breakfast only, such as black tea or coffee and toast. Some doctors recommend eating a small amount of fat (such as butter or margarine) with breakfast, which will empty the gallbladder and potentially decrease the risk of gallbladder injury during the biopsy.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      LIVER BIOPSY PROCEDURE",
"     </span>",
"    </p>",
"    <p>",
"     Most liver biopsies are done in a hospital. Upon arrival for the biopsy (usually in the early morning), a doctor or nurse will review your medical history, including medications and allergies. You may have an IV line placed into a vein so that fluid and medicine can be given if needed.",
"    </p>",
"    <p>",
"     You may be given medicines to minimize discomfort and anxiety. Because your cooperation is needed during a liver biopsy, you will not be put to sleep.",
"    </p>",
"    <p>",
"     The biopsy itself only takes a few seconds as the biopsy needle is passed quickly in and out of the liver. A small bandage will be applied to the biopsy site; stitches are not needed.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      LIVER BIOPSY COMPLICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     A liver biopsy is a very safe procedure when performed by an experienced doctor. The most common problems include mild pain and a minor decrease in blood pressure. More serious complications, such as bleeding, infection, and injury to nearby organs, are very rare.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      CARE AFTER LIVER BIOPSY",
"     </span>",
"    </p>",
"    <p>",
"     Following the liver biopsy, you will be asked to lie on your right side, and a nurse will monitor your blood pressure and pulse periodically. Many people watch television or a video, read, or talk with friends or family.",
"    </p>",
"    <p>",
"     You will need to arrange to have someone take you home after the biopsy because sedative medications are often used. A friend or family member can also help pass the time during the few hours of observation following the biopsy.",
"    </p>",
"    <p>",
"     In addition to resting the day of the biopsy, you should plan to take it easy for the next five to seven days. In general, you should not lift more than 15 to 20 pounds for a week, avoid blood thinning medication for several days, and call with any concerning symptoms, including the following:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Severe pain at the biopsy site or shoulder",
"      </li>",
"      <li>",
"       Shortness of breath",
"      </li>",
"      <li>",
"       Chest pain",
"      </li>",
"      <li>",
"       Bleeding from the biopsy site",
"      </li>",
"      <li>",
"       Fever (temperature greater than 100.4&ordm;F or 38&ordm;C)",
"      </li>",
"      <li>",
"       Abdominal pain",
"      </li>",
"      <li>",
"       Weakness, sweating",
"      </li>",
"      <li>",
"       Heart palpitations",
"      </li>",
"      <li>",
"       Blood in your stool or black tarry stool",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Biopsy results",
"     </span>",
"     &nbsp;&mdash;&nbsp;The biopsy report is usually available within a few days to a week after the biopsy. Call your doctor or make a follow-up appointment to discuss the results of the biopsy and what treatment (if any) is needed.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3498663728\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6600455\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/25/24979?source=see_link\">",
"      Patient information: Cirrhosis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/17/34066?source=see_link\">",
"      Patient information: Jaundice in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?43/42/44706?source=see_link\">",
"      Patient information: Liver cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/6/23651?source=see_link\">",
"      Patient information: Toxic hepatitis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/34/2594?source=see_link\">",
"      Patient information: Primary biliary cirrhosis (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6600481\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/47/12018?source=see_link\">",
"      Patient information: Nonalcoholic steatohepatitis (NASH) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/45/31447?source=see_link\">",
"      Patient information: Hepatitis B (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/4/17478?source=see_link\">",
"      Patient information: Hepatitis C (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/41/2709?source=see_link\">",
"      Patient information: Hemochromatosis (hereditary iron overload) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/56/25474?source=see_link\">",
"      Patient information: Autoimmune hepatitis (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/58/29608?source=see_link\">",
"      Percutaneous, fine-needle aspiration, and laparoscopic liver biopsy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/37/9814?source=see_link\">",
"      Transjugular liver biopsy",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/ency/article/003895.htm\">",
"      www.nlm.nih.gov/medlineplus/ency/article/003895.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://digestive.niddk.nih.gov/ddiseases/pubs/liverbiopsy/\">",
"      file://digestive.niddk.nih.gov/ddiseases/pubs/liverbiopsy/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?4/39/4721/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 2, 2010.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?4/39/4721?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4721/abstract/1\">",
"      Grant A, Neuberger J. Guidelines on the use of liver biopsy in clinical practice. British Society of Gastroenterology. Gut 1999; 45 Suppl 4:IV1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4721/abstract/2\">",
"      Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4721/abstract/3\">",
"      Firpi RJ, Soldevila-Pico C, Abdelmalek MF, et al. Short recovery time after percutaneous liver biopsy: should we change our current practices? Clin Gastroenterol Hepatol 2005; 3:926.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f4_39_4721=[""].join("\n");
var outline_f4_39_4721=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           LIVER BIOPSY OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           REASONS FOR LIVER BIOPSY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           LIVER BIOPSY PREPARATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           LIVER BIOPSY PROCEDURE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           LIVER BIOPSY COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           CARE AFTER LIVER BIOPSY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/54/40804\" title=\"figure 1\">",
"           Abdomen anatomy adult PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f4_39_4722="Dysplastic RBC in MDS";
var content_f4_39_4722=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F85882&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F85882&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Dysplastic red blood cell in myelodysplastic syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 380px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Dysplastic nucleated red blood cell, peripheral blood. The nucleus shows an abnormal shape and size.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Farhi DC. Myelodysplastic syndromes. In: Pathology of Bone Marrow and Blood Cells, 2nd ed, Farhi DC (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_39_4722=[""].join("\n");
var outline_f4_39_4722=null;
var title_f4_39_4723="Linitis plastica UGI";
var content_f4_39_4723=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F79963&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F79963&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Linitis plastica of the stomach as seen on upper gastrointestinal (UGI) series",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 277px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Upper gastrointestinal study reveals fixed narrowing of the entire proximal stomach (arrows) due to submucosal invasion by a gastric cancer. Other malignancies, such as breast and lung metastases to the stomach, may have a similar appearance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal upper GI series",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 286px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal air-contrast upper gastrointestinal study showing normal gastric folds and small intestinal anatomy, and no masses.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul C Schroy III, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_39_4723=[""].join("\n");
var outline_f4_39_4723=null;
var title_f4_39_4724="NK cell deficiency syndromes: Treatment";
var content_f4_39_4724=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   NK cell deficiency syndromes: Treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/39/4724/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/39/4724/contributors\">",
"     Jordan S Orange, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/39/4724/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/39/4724/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/39/4724/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/39/4724/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/39/4724/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;NK cell deficiency syndromes are rare disorders in which NK cells are absent, deficient, or dysfunctional, in the absence of any other identifiable immunodeficiency, genetic disorder, or medication known to affect NK cells.",
"   </p>",
"   <p>",
"    The management of patients with these disorders is discussed here. The biology of NK cells, the clinical manifestations of NK cell disorders, and the evaluation of patients suspected of having NK cell defects are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30889?source=see_link\">",
"     \"NK cell deficiency syndromes: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy for patients with NK cell deficiency syndromes is largely empiric, due to the small numbers of cases described in the literature. Active infections must be identified and treated aggressively, as with any immune disorder. The use of specific therapies is based either on theoretical utility or anecdotal reports of benefit (",
"    <a class=\"graphic graphic_table graphicRef68545 \" href=\"UTD.htm?26/23/27003\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANTIVIRAL PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;NK cell disorders are characterized clinically by susceptibility to severe",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    recurrent infection with herpes viruses, including varicella zoster virus (VZV), Herpes simplex virus (HSV) I and II, Epstein Barr virus (EBV), and cytomegalovirus (CMV). There is also a marked susceptibility in some patients to Human Papilloma Viruses.",
"   </p>",
"   <p>",
"    Prophylactic antiviral regimens should be tailored to the infectious history of the individual patient. Serologic tests should be performed to determine if an NK cell deficient individual has experienced infections with known herpesviruses. In our clinic, we assess for past exposure to the following viruses:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      VZV",
"     </li>",
"     <li>",
"      HSV I and II",
"     </li>",
"     <li>",
"      CMV",
"     </li>",
"     <li>",
"      EBV",
"     </li>",
"     <li>",
"      Human herpes virus 6 (HHV 6)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Evidence of past exposure indicates that the patient is able to contain that particular pathogen to some extent and thus does not require prophylaxis against that pathogen.",
"   </p>",
"   <p>",
"    If a patient with NK cell deficiency is naive to HSV or CMV, however, then we suggest administering permanent prophylaxis with an appropriate antiviral agent (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    for HSV,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    for CMV). There are no studies assessing the",
"    <span class=\"nowrap\">",
"     risk/benefit",
"    </span>",
"    ratio of such an approach, but in the absence of this information, the author would suggest indefinite prophylaxis.",
"   </p>",
"   <p>",
"    In those for whom they are prescribed, the prophylactic regimens are continued indefinitely. Doses are derived from regimens used in more common secondary immunodeficiency diseases such as AIDS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=see_link\">",
"     \"Medical management of immune deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36488?source=see_link\">",
"     \"Treatment of herpes simplex virus type 1 infection in immunocompetent patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Breakthrough infectious episodes should be treated with higher dose treatment regimens, or with the intravenous form of the drug, where appropriate. This suggestion is based upon anecdotal clinical experiences described in case reports.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     IMMUNIZATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of recombinant HPV vaccine is suggested, due to the potential risk of severe disease in those with NK cell defects. In contrast, we would advise consideration of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    on a case-by-case basis. The varicella vaccine contains live attenuated virus and thus could theoretically place the patient at risk for disseminated infection. However, no cases of disseminated infection with vaccine-strain varicella have been reported in patients with isolated NK cell deficiencies who were vaccinated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     IMMUNOGLOBULIN REPLACEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with ANKD, CKND, or FNKD who have experienced a life-threatening infection with one of the viruses that pose a threat to these patients and are naive to others, it is reasonable to consider regular immune globulin replacement therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4724/abstract/1\">",
"     1",
"    </a>",
"    ]. Theoretically, the antiviral antibodies contained in gammaglobulin would provide some protection against these viruses, including herpes viruses for which there are no specific prophylactic antiviral therapies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=see_link\">",
"     \"Immune globulin therapy in primary immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     POSSIBLE ADJUNCTIVE THERAPIES FOR FNKD",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are relatively few therapies that are known to increase NK cell activities. These are of potential value in patients with FKND.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Interleukin-2",
"    </span>",
"    &nbsp;&mdash;&nbsp;One biologic agent that is capable of increasing NK cell activities is interleukin-2 (IL-2) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4724/abstract/2\">",
"     2",
"    </a>",
"    ]. IL-2 has been used in individuals with malignancy and HIV infection and has been shown to increase NK cell activity. It has also been reported to have clinical benefit or increase NK cell activity in diseases having impaired NK cell function [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4724/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon these observations, it is reasonable to evaluate the in vitro responsiveness of NK cells to IL-2 in a patient with FNKD. If there is a convincing in vitro response (ie, a greater than twofold increase in NK cell cytolytic activity), then low dose IL-2 therapy may be considered as an experimental adjunctive treatment. We suggest that this be administered only by clinicians with experience in the use of this agent.",
"   </p>",
"   <p>",
"    As demonstrated in other diseases, there are a variety of successful IL-2 treatment regimens that increase NK cell function [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4724/abstract/3,5,6\">",
"     3,5,6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the author's unpublished, anecdotal experience, IL-2 (at a dose of 0.5 to 1 million",
"      <span class=\"nowrap\">",
"       units/m2",
"      </span>",
"      given subcutaneously daily for five consecutive days) can induce an increase in NK cell cytotoxic activity in those patients who have been shown to respond in vitro. If the patient appears to improve, the treatment can be repeated every seven to eight weeks.",
"     </li>",
"     <li>",
"      Alternatively, a dose of 0.5 to 1 million",
"      <span class=\"nowrap\">",
"       units/m2",
"      </span>",
"      can be given subcutaneously three times per week as continuous therapy. This can help induce and sustain NK cell function in some patients. Aside from injection site reactions, either regimen is relatively well tolerated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Interferon alfa",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29576?source=see_link\">",
"     Interferon alfa-2b",
"    </a>",
"    enhances the cytotoxic activity of NK cells, and systemic treatment of a patient with refractory periungual warts and NK cell dysfunction resulted in dramatic improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4724/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. This agent warrants further study. Aside from use in patients with NK cell dysfunction and intractable warts, use of Interferon alfa-2b is not recommended outside of investigational protocols at this time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     HEMATOPOIETIC CELL TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with particularly severe past infections and acceptably matched donors, hematopoietic cell transplantation may be considered in an attempt to correct the presumed hematopoietic defect. The severity of the patient's illness would have to be balanced against the risks of transplant. Successful hematopoietic stem cell transplantation from a matched, unrelated donor was reported in a seven year-old girl who had suffered severe disseminated varicella infection at age four, which was complicated by encephalitis, vasculitis, and macrophage activation syndrome with multiple organ involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4724/abstract/9\">",
"     9",
"    </a>",
"    ]. Laboratory evaluation prior to transplantation revealed an absence of both NK cells and B cells. The child was free of infections and had a normal lymphocyte profile four years after transplantation.",
"   </p>",
"   <p>",
"    Other case reports have described patients who survived initial transplantation but reportedly succumbed to complications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1066?source=see_link\">",
"     \"Hematopoietic cell transplantation for primary immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of specific therapies is based either on theoretical utility or anecdotal reports of benefit (",
"    <a class=\"graphic graphic_table graphicRef68545 \" href=\"UTD.htm?26/23/27003\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with ANKD or CKND who have no evidence of exposure or immunity to HSV or CMV, we suggest lifelong prophylaxis with antiviral agents for protection against these infections (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Antiviral prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with ANKD, CKND, or FNKD, we suggest administration of recombinant HPV vaccine (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Immunizations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with ANKD, CKND, or FNKD who have experienced a life-threatening infection with one herpesvirus and are naive to other herpesviruses, we suggest immunoglobulin replacement therapy because the antiviral antibodies it contains should provide some protection against viral infections (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Immunoglobulin replacement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the patient with functional NK cell deficiency, in whom there is a convincing in vitro response to interleukin-2 (ie, a greater than twofold increase in NK cell cytolytic activity), low dose IL-2 therapy is an experimental therapy that may augment NK cell function. The optimal dose is not known, although the author has successfully administered 0.5 to 1 million units of",
"      <span class=\"nowrap\">",
"       IL-2/m2,",
"      </span>",
"      subcutaneously, using two different schedules. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Interleukin-2'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with severe and refractory warts, we suggest the administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29576?source=see_link\">",
"       interferon alfa-2b",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The use of this agent for other conditions associated with NK cell deficiencies should be limited to investigational protocols. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Possible adjunctive therapies for FNKD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with particularly severe histories and acceptably matched donors, hematopoietic cell transplantation may correct the presumed hematopoietic defect. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Hematopoietic cell transplantation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4724/abstract/1\">",
"      Biron CA, Nguyen KB, Pien GC, et al. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 1999; 17:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4724/abstract/2\">",
"      Lotzov&aacute; E, Savary CA, Schachner JR, et al. Generation of cytotoxic NK cells in peripheral blood and bone marrow of patients with acute myelogenous leukemia after continuous infusion with recombinant interleukin-2. Am J Hematol 1991; 37:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4724/abstract/3\">",
"      Azuma H, Oshima M, Ito K, et al. Impaired interleukin-2 production in T-cells from a patient with Wiskott-Aldrich syndrome: basis of clinical effect of interleukin-2 replacement therapy. Eur J Pediatr 2000; 159:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4724/abstract/4\">",
"      Orange JS, Brodeur SR, Jain A, et al. Deficient natural killer cell cytotoxicity in patients with IKK-gamma/NEMO mutations. J Clin Invest 2002; 109:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4724/abstract/5\">",
"      Meropol NJ, Porter M, Blumenson LE, et al. Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicity. Clin Cancer Res 1996; 2:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4724/abstract/6\">",
"      Toren A, Nagler A, Rozenfeld-Granot G, et al. Amplification of immunological functions by subcutaneous injection of intermediate-high dose interleukin-2 for 2 years after autologous stem cell transplantation in children with stage IV neuroblastoma. Transplantation 2000; 70:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4724/abstract/7\">",
"      Mossman KL, Ashkar AA. Herpesviruses and the innate immune response. Viral Immunol 2005; 18:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4724/abstract/8\">",
"      Cac NN, Ballas ZK. Recalcitrant warts, associated with natural killer cell dysfunction, treated with systemic IFN-alpha. J Allergy Clin Immunol 2006; 118:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4724/abstract/9\">",
"      Notarangelo LD, Mazzolari E. Natural killer cell deficiencies and severe varicella infection. J Pediatr 2006; 148:563.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3922 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-18C9BB78CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_39_4724=[""].join("\n");
var outline_f4_39_4724=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANTIVIRAL PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      IMMUNIZATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      IMMUNOGLOBULIN REPLACEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      POSSIBLE ADJUNCTIVE THERAPIES FOR FNKD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Interleukin-2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Interferon alfa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      HEMATOPOIETIC CELL TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3922\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3922|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/23/27003\" title=\"table 1\">",
"      Management NK cell deficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1066?source=related_link\">",
"      Hematopoietic cell transplantation for primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14087?source=related_link\">",
"      Immune globulin therapy in primary immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=related_link\">",
"      Medical management of immune deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30889?source=related_link\">",
"      NK cell deficiency syndromes: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36488?source=related_link\">",
"      Treatment of herpes simplex virus type 1 infection in immunocompetent patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_39_4725="Cushing's syndrome in pregnancy";
var content_f4_39_4725=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cushing's syndrome in pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/39/4725/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/39/4725/contributors\">",
"     Lynnette K Nieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/39/4725/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/39/4725/contributors\">",
"     Andre Lacroix, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/39/4725/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/39/4725/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/39/4725/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/39/4725/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hypercortisolemia in Cushing's syndrome is usually due to a corticotropin (ACTH)-producing pituitary tumor (Cushing's disease), ectopic ACTH secretion by a nonpituitary tumor, or cortisol secretion by an adrenal adenoma or carcinoma. There are also very rare tumors that secrete corticotropin-releasing hormone (CRH) ectopically, and occasional cases are caused by cortisol secretion by ACTH-independent macronodular or micronodular hyperplasia of the adrenal cortex. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31225?source=see_link\">",
"     \"Establishing the cause of Cushing's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review issues related to Cushing's syndrome in pregnancy. The clinical manifestations, diagnosis, and treatment of Cushing's syndrome in nonpregnant patients are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=see_link\">",
"     \"Epidemiology and clinical manifestations of Cushing's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21913?source=see_link\">",
"     \"Establishing the diagnosis of Cushing's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1016?source=see_link\">",
"     \"Overview of the treatment of Cushing's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CUSHING'S SYNDROME AND PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cushing's syndrome is associated with a high prevalence (up to 75 percent) of ovulatory disturbances induced by cortisol excess [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4725/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. As a result, women with untreated Cushing's syndrome rarely become pregnant [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4725/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency of ACTH-independent cases is increased in pregnant as compared to non-pregnant individuals. Of the approximately 136 reported cases, approximately 60 percent had ACTH-independent Cushing's syndrome (48 percent adenoma and 10 percent carcinoma); most of the rest had Cushing's disease or bilateral adrenal hyperplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4725/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Five pregnant women with the ectopic ACTH syndrome have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4725/abstract/1,3,5-7\">",
"     1,3,5-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reason for this unusual pattern is not known. Pure cortisol-secreting adrenal adenomas may interfere with reproductive function less than the mixed cortisol and androgen excess produced by adrenal carcinomas or ACTH-dependent adrenal hyperplasia. In addition, most patients with the ectopic ACTH syndrome are men [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4725/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to preexisting disease, pregnancy appears to induce Cushing's syndrome in occasional cases. In a small number of patients, Cushing's syndrome remits completely postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4725/abstract/2,3,8\">",
"     2,3,8",
"    </a>",
"    ] and, in a few reported cases, recurred during multiple pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4725/abstract/9\">",
"     9",
"    </a>",
"    ]. Possible mechanisms include placental CRH [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4725/abstract/10\">",
"     10",
"    </a>",
"    ], ectopic expression in the adrenal cortex of receptors for luteinizing",
"    <span class=\"nowrap\">",
"     hormone/chorionic",
"    </span>",
"    gonadotropin [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4725/abstract/11,12\">",
"     11,12",
"    </a>",
"    ], and estrogen-dependent nodular adrenal hyperplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4725/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/61/13274?source=see_link\">",
"     \"Maternal endocrine and metabolic adaptation to pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/35/22072?source=see_link\">",
"     \"Cushing's syndrome due to primary pigmented nodular adrenocortical disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The fetus is partially protected from the hypercortisolemia because placental 11-beta-hydroxysteroid dehydrogenase converts 85 percent of maternal cortisol to biologically inactive cortisone [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4725/abstract/5\">",
"     5",
"    </a>",
"    ]. However, untreated Cushing's syndrome has been associated with spontaneous abortion, premature delivery and, rarely, neonatal adrenal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4725/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Maternal complications also can occur. These include hypertension in nearly 70 percent, gestational diabetes in one quarter of patients, preeclampsia and, rarely heart failure. Two maternal deaths have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4725/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of Cushing's syndrome during pregnancy may be masked since some of the symptoms and signs of this disorder (eg, weight gain, hypertension, striae) can also occur in normal pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4725/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, biochemical changes during normal pregnancy can interfere with the diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum total and free cortisol concentrations and urinary cortisol excretion are increased in pregnant women, but the diurnal rhythm in serum cortisol is maintained and urinary 17-OH corticosteroid excretion is normal [",
"      <a class=\"abstract\" href=\"UTD.htm?4/39/4725/abstract/3\">",
"       3",
"      </a>",
"      ]. One study in normal women reported that plasma cortisol values in pregnancy progressed from 14.9",
"      <span class=\"nowrap\">",
"       +/-",
"      </span>",
"      3.4",
"      <span class=\"nowrap\">",
"       ng/dL",
"      </span>",
"      at 12 weeks to 35.2",
"      <span class=\"nowrap\">",
"       +/-",
"      </span>",
"      9.0",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      at 26 weeks' gestation and changed minimally thereafter. This same study found a two- to threefold increase in urinary free cortisol (UFC) in the second and third trimesters [",
"      <a class=\"abstract\" href=\"UTD.htm?4/39/4725/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      While measurement of bedtime or midnight plasma or salivary cortisol may be helpful in establishing hypercortisolism in non-pregnant patients, no criteria are available for their interpretation during gestation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21913?source=see_link\">",
"       \"Establishing the diagnosis of Cushing's syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Plasma ACTH concentrations are slightly low during early pregnancy, but gradually increase to slightly above normal, due at least in part to placental ACTH secretion.",
"     </li>",
"     <li>",
"      Suppression of cortisol by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      is blunted, particularly in the second and third trimesters [",
"      <a class=\"abstract\" href=\"UTD.htm?4/39/4725/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The evaluation of suspected Cushing's syndrome in pregnancy is the same as that for non-pregnant patients. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21913?source=see_link\">",
"     \"Establishing the diagnosis of Cushing's syndrome\"",
"    </a>",
"    .) However, there are no pregnancy-specific guidelines for interpretation of these tests. Because of the blunted response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    that is normal in gestation, it is probably not a good screening test in pregnancy because of the risk for false positive results. The normal increase in UFC during the second and third trimesters suggests that the diagnosis of Cushing's syndrome cannot be established unless UFC excretion is at least threefold elevated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Differential diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Because of the persistent elevations of ACTH in pregnancy, a suppressed ACTH is not always found in independent causes of Cushing's syndrome. Thus, while its measurement may be useful (showing suppression), lack of a suppressed value does not exclude an ACTH-independent cause.",
"     </li>",
"     <li>",
"      There are limited data on the responses to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      , 8 mg, of women with adrenal causes of Cushing's syndrome and pituitary adenomas. In general, those with an adrenal etiology do not suppress [",
"      <a class=\"abstract\" href=\"UTD.htm?4/39/4725/abstract/16-18\">",
"       16-18",
"      </a>",
"      ], while those with Cushing's disease do suppress serum cortisol [",
"      <a class=\"abstract\" href=\"UTD.htm?4/39/4725/abstract/4,19,20\">",
"       4,19,20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Because adrenal forms of Cushing's syndrome are common in pregnancy, it is reasonable to perform an adrenal ultrasound to look for a mass, as well as an ACTH level and high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      suppression test, as an initial evaluation.",
"     </li>",
"     <li>",
"      CRH stimulation and IPSS testing have been performed rarely in pregnant patients [",
"      <a class=\"abstract\" href=\"UTD.htm?4/39/4725/abstract/4\">",
"       4",
"      </a>",
"      ]. MRI cannot be performed in the first trimester because of concerns about potential adverse fetal effects; during the remainder of gestation it is not commonly given with gadolinium contrast, which is FDA-labeled as a class C drug. Thus, while MRI may identify a pituitary macroadenoma, it is potentially less sensitive, without gadolinium contrast, in pregnant patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, approximately 60 percent of patients have ACTH-independent Cushing's syndrome (45 percent adenoma and 15 percent carcinoma). Adrenal surgery has been performed at 16 to 21 weeks of pregnancy without complicating the pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4725/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. While there is no clear evidence that early treatment is more beneficial than later treatment, this is likely because treatment is generally begun late. In the authors' opinion, early second trimester surgical treatment would be optimal. For women who do not want surgery or are diagnosed later, maternal hypercortisolism can be controlled with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4725/abstract/3,21\">",
"     3,21",
"    </a>",
"    ]. It is reasonable to consider early delivery of the fetus when complications of eclampsia supervene [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4725/abstract/3,9,22\">",
"     3,9,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other therapeutic options for ACTH-independent disease are associated with potential problems:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"       Ketoconazole",
"      </a>",
"      is teratogenic and toxic to animal embryos but has been used successfully and without harm to fetuses from as early as the seventh week of pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?4/39/4725/abstract/23,24\">",
"       23,24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/58/16293?source=see_link\">",
"       Mitotane",
"      </a>",
"      should not be given to pregnant women [",
"      <a class=\"abstract\" href=\"UTD.htm?4/39/4725/abstract/25\">",
"       25",
"      </a>",
"      ], although it was used in one woman without complications [",
"      <a class=\"abstract\" href=\"UTD.htm?4/39/4725/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For pregnant women with Cushing's disease, transsphenoidal surgery and pituitary radiation have both been used without complicating the pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4725/abstract/1,19,27\">",
"     1,19,27",
"    </a>",
"    ]. In women treated with radiation, the hypercortisolism can be ameliorated or controlled by the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    during and after treatment, while awaiting the full benefit of radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4725/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treating the Cushing's syndrome does not reduce the frequency of intrauterine growth restriction (about 30 percent) or premature birth (about 65 percent), but it does appear to prevent stillborn deliveries (about 10 percent with treatment) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4725/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Up to 75 percent of women with Cushing's syndrome have ovulatory disorders as a result of their cortisol excess. Thus, women with untreated Cushing's syndrome rarely become pregnant. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Cushing's syndrome and pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Of those who do become pregnant, approximately 60 percent have ACTH-independent hypercortisolism (primarily adrenal adenomas). This pattern is different from that seen in nonpregnant individuals with Cushing's syndrome, the majority of whom have ACTH-dependent hypercortisolism (ACTH-secreting pituitary tumors). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Cushing's syndrome and pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The evaluation of suspected Cushing's syndrome in pregnancy is the same as that for non-pregnant patients. However, there are no pregnancy-specific guidelines for interpretation of these tests. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adrenal surgery for primary adrenal tumors has been performed at 16 to 21 weeks of pregnancy without complicating the pregnancy. For women who do not want surgery or are diagnosed later, maternal hypercortisolism can be controlled with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"       metyrapone",
"      </a>",
"      . It is reasonable to consider early delivery of the fetus when complications of eclampsia supervene. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4725/abstract/1\">",
"      Aron DC, Schnall AM, Sheeler LR. Cushing's syndrome and pregnancy. Am J Obstet Gynecol 1990; 162:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4725/abstract/2\">",
"      Buescher MA, McClamrock HD, Adashi EY. Cushing syndrome in pregnancy. Obstet Gynecol 1992; 79:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4725/abstract/3\">",
"      Buescher, MA. Cushing's syndrome in pregnancy. Endocrinologist 1996; 6:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4725/abstract/4\">",
"      Lindsay JR, Jonklaas J, Oldfield EH, Nieman LK. Cushing's syndrome during pregnancy: personal experience and review of the literature. J Clin Endocrinol Metab 2005; 90:3077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4725/abstract/5\">",
"      Guilhaume B, Sanson ML, Billaud L, et al. Cushing's syndrome and pregnancy: aetiologies and prognosis in twenty-two patients. Eur J Med 1992; 1:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4725/abstract/6\">",
"      Hadden DR. Adrenal disorders of pregnancy. Endocrinol Metab Clin North Am 1995; 24:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4725/abstract/7\">",
"      Cohade C, Broussaud S, Louiset E, et al. Ectopic Cushing's syndrome due to a pheochromocytoma: a new case in the post-partum and review of literature. Gynecol Endocrinol 2009; 25:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4725/abstract/8\">",
"      Close CF, Mann MC, Watts JF, Taylor KG. ACTH-independent Cushing's syndrome in pregnancy with spontaneous resolution after delivery: control of the hypercortisolism with metyrapone. Clin Endocrinol (Oxf) 1993; 39:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4725/abstract/9\">",
"      H&aacute;na V, Dokoupilov&aacute; M, Marek J, Plavka R. Recurrent ACTH-independent Cushing's syndrome in multiple pregnancies and its treatment with metyrapone. Clin Endocrinol (Oxf) 2001; 54:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4725/abstract/10\">",
"      Jones SA, Brooks AN, Challis JR. Steroids modulate corticotropin-releasing hormone production in human fetal membranes and placenta. J Clin Endocrinol Metab 1989; 68:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4725/abstract/11\">",
"      Lacroix A, Ndiaye N, Tremblay J, Hamet P. Ectopic and abnormal hormone receptors in adrenal Cushing's syndrome. Endocr Rev 2001; 22:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4725/abstract/12\">",
"      Wy LA, Carlson HE, Kane P, et al. Pregnancy-associated Cushing's syndrome secondary to a luteinizing hormone/human chorionic gonadotropin receptor-positive adrenal carcinoma. Gynecol Endocrinol 2002; 16:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4725/abstract/13\">",
"      Caticha O, Odell WD, Wilson DE, et al. Estradiol stimulates cortisol production by adrenal cells in estrogen-dependent primary adrenocortical nodular dysplasia. J Clin Endocrinol Metab 1993; 77:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4725/abstract/14\">",
"      Carr BR, Parker CR Jr, Madden JD, et al. Maternal plasma adrenocorticotropin and cortisol relationships throughout human pregnancy. Am J Obstet Gynecol 1981; 139:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4725/abstract/15\">",
"      Odagiri E, Ishiwatari N, Abe Y, et al. Hypercortisolism and the resistance to dexamethasone suppression during gestation. Endocrinol Jpn 1988; 35:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4725/abstract/16\">",
"      Barasch E, Sztern M, Spinrad S, et al. Pregnancy and Cushing's syndrome: example of endocrine interaction. Isr J Med Sci 1988; 24:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4725/abstract/17\">",
"      Abrahamson MJ, Miller JL, Alperstein AL, Barron JL. Cushing's syndrome in pregnancy. A case report. S Afr Med J 1986; 69:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4725/abstract/18\">",
"      Da Motta LA, Motta LD, Barbosa AM, et al. Two pregnancies in a Cushing's syndrome. Case report. Panminerva Med 1991; 33:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4725/abstract/19\">",
"      Casson IF, Davis JC, Jeffreys RV, et al. Successful management of Cushing's disease during pregnancy by transsphenoidal adenectomy. Clin Endocrinol (Oxf) 1987; 27:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4725/abstract/20\">",
"      Ross RJ, Chew SL, Perry L, et al. Diagnosis and selective cure of Cushing's disease during pregnancy by transsphenoidal surgery. Eur J Endocrinol 1995; 132:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4725/abstract/21\">",
"      Blanco C, Maqueda E, Rubio JA, Rodriguez A. Cushing's syndrome during pregnancy secondary to adrenal adenoma: metyrapone treatment and laparoscopic adrenalectomy. J Endocrinol Invest 2006; 29:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4725/abstract/22\">",
"      Orth DN, Liddle GW. Results of treatment in 108 patients with Cushing's syndrome. N Engl J Med 1971; 285:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4725/abstract/23\">",
"      Amado JA, Pesquera C, Gonzalez EM, et al. Successful treatment with ketoconazole of Cushing's syndrome in pregnancy. Postgrad Med J 1990; 66:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4725/abstract/24\">",
"      Berwaerts J, Verhelst J, Mahler C, Abs R. Cushing's syndrome in pregnancy treated by ketoconazole: case report and review of the literature. Gynecol Endocrinol 1999; 13:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4725/abstract/25\">",
"      Leiba S, Weinstein R, Shindel B, et al. The protracted effect of o,p'-DDD in Cushing's disease and its impact on adrenal morphogenesis of young human embryo. Ann Endocrinol (Paris) 1989; 50:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4725/abstract/26\">",
"      Knappe G, Gerl H, Ventz M, Rohde W. [The long-term therapy of hypothalamic-hypophyseal Cushing's syndrome with mitotane (o,p'-DDD)]. Dtsch Med Wochenschr 1997; 122:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4725/abstract/27\">",
"      Kriplani A, Buckshee K, Ammini AC. Cushing syndrome complicating pregnancy. Aust N Z J Obstet Gynaecol 1993; 33:428.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 139 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-340D2F8564-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_39_4725=[""].join("\n");
var outline_f4_39_4725=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CUSHING'S SYNDROME AND PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/35/22072?source=related_link\">",
"      Cushing's syndrome due to primary pigmented nodular adrenocortical disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22282?source=related_link\">",
"      Epidemiology and clinical manifestations of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31225?source=related_link\">",
"      Establishing the cause of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21913?source=related_link\">",
"      Establishing the diagnosis of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/61/13274?source=related_link\">",
"      Maternal endocrine and metabolic adaptation to pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1016?source=related_link\">",
"      Overview of the treatment of Cushing's syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_39_4726="Crawford classification of thoracoabdominal aortic aneurysms";
var content_f4_39_4726=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F66037&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F66037&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 474px\">",
"   <div class=\"ttl\">",
"    Crawford classification of thoracoabdominal aortic aneurysms",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 454px; height: 358px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The Crawford classification is based on the extent of aortic involvement. Extent I aneurysms begin above the sixth intercostal space, usually near the left subclavian artery, and extend down to encompass the aorta at the origins of the celiac axis and superior mesenteric arteries; although the renal arteries may also be involved, the aneurysm does not extend into the infrarenal segment. Extent II aneurysms also arise above the sixth intercostal space, but extend distally into the infrarenal aorta, often to the level of the aortic bifurcation. Extent III aneurysms begin in the distal half of the descending thoracic aorta, below the sixth intercostal space, and extend into the abdominal aorta. Extent IV aneurysms generally involve the entire abdominal aorta from the level of the diaphragm to the bifurcation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: the Society of Thoracic Surgeons. The Annals of Thoracic Surgery 2001; 71:1233-8.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_39_4726=[""].join("\n");
var outline_f4_39_4726=null;
var title_f4_39_4727="Sturge-Weber syndrome";
var content_f4_39_4727=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sturge-Weber syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/39/4727/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/39/4727/contributors\">",
"     John B Bodensteiner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/39/4727/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/39/4727/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/39/4727/contributors\">",
"     Moise L Levy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/39/4727/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/39/4727/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/39/4727/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sturge-Weber syndrome (SWS) is a rare congenital vascular disorder characterized by facial capillary malformation (port wine stain) and associated capillary-venous malformations affecting the brain and eye [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4727/abstract/1\">",
"     1",
"    </a>",
"    ]. It is",
"    <strong>",
"     not",
"    </strong>",
"    a heritable disorder. Thus, recurrence is unlikely.",
"   </p>",
"   <p>",
"    The etiology of SWS is unknown. One hypothesis is that the capillary-venous malformations, historically called angiomata, result from somatic mutations in fetal ectodermal tissues that cause inappropriate control or maturation of capillary blood vessel formation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4727/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sturge-Weber syndrome (SWS) is characterized by a facial capillary malformation (port wine stain) and an associated leptomeningeal capillary-venous malformation (leptomeningeal angioma) involving the brain and eye [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4727/abstract/3\">",
"     3",
"    </a>",
"    ]. These vascular malformations are associated with specific neurologic and ocular abnormalities.",
"   </p>",
"   <p>",
"    The neurologic features of SWS may be progressive and include seizures, focal neurologic deficits, and mental retardation. Visual field defects are common when the occipital cortex is affected. These manifestations occur with variable severity. Hydrocephalus also may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4727/abstract/4\">",
"     4",
"    </a>",
"    ]. This complication is thought to result from increased venous pressure caused by thrombosis of the deep venous channels or extensive arteriovenous anastomoses. A small proportion of patients have no neurologic abnormalities.",
"   </p>",
"   <p>",
"    The reasons for neurologic progression in SWS are uncertain. A possible mechanism is hypoxic-ischemic injury to tissue adjacent to the leptomeningeal capillary-venous malformation. This is supported by findings in some patients of reduced cellular glucose metabolism, possibly resulting from decreased cerebral blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4727/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Other proposed mechanisms are venous occlusion and increased venous pressure.",
"   </p>",
"   <p>",
"    Ocular features of SWS include glaucoma and capillary-venous vascular malformations of the conjunctiva, episclera, choroid, and retina [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4727/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Port wine stain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous port wine stain (capillary malformation) is the most common type of vascular malformation, occurring in 0.3 percent of newborn infants (",
"    <a class=\"graphic graphic_picture graphicRef73343 \" href=\"UTD.htm?1/61/2002\">",
"     picture 1",
"    </a>",
"    ). However, only a small proportion of children with port wine stains have SWS.",
"   </p>",
"   <p>",
"    In SWS, the port wine stain typically is present on the forehead and upper eyelid, primarily in the distribution of the first or second division of the trigeminal nerve [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4727/abstract/9\">",
"     9",
"    </a>",
"    ]. In one report, 274 patients had port wine stains located in the distribution of the trigeminal nerve, and involvement of the eye or central nervous system was noted in 22 (8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4727/abstract/10\">",
"     10",
"    </a>",
"    ]. All 22 patients of these patients had a port wine stain in the first or second division of the trigeminal nerve. Although traditionally considered important in determining meningeal involvement risk, the location of the capillary malformation (port wine stain) on the face is not a good indicator of the risk of an underlying meningeal capillary malformation. However, the mid-face and the meninges do share a common embryological origin [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4727/abstract/3\">",
"     3",
"    </a>",
"    ]. Extension of the skin lesion to both sides of the face and the trunk and extremities is common.",
"   </p>",
"   <p>",
"    The skin lesion usually is obvious at birth. However, its appearance changes with age and its size increases as the patient grows. In the newborn, the lesion is flat and usually light pink in color. It typically darkens with age to a deep red, port wine appearance, and vascular ectasias develop (",
"    <a class=\"graphic graphic_picture graphicRef58831 \" href=\"UTD.htm?21/53/22367\">",
"     picture 2",
"    </a>",
"    ). The vascular ectasias produce nodularity and superficial blebbing, which lead to overgrowth of the underlying soft tissues and sometimes the bone. Dental abnormalities may occur as a result of gingival thickening if this area is affected. By the fifth decade, 65 percent of patients with a facial port wine stain have hypertrophy and nodularity within the lesion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Leptomeningeal vascular malformation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A leptomeningeal capillary-venous malformation (historically referred to as leptomeningeal angioma) occurs in 10 to 20 percent of cases when a typical facial lesion is present. The intracerebral capillary-venous malformation usually occurs on the same side as the port wine stain. The parietal and occipital areas are affected most commonly, although any portion of the cerebrum can be involved. Leptomeningeal capillary-venous malformation seldom occurs without an accompanying facial capillary malformation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4727/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathologic appearance of the leptomeninges includes thickening and discoloration caused by the increased vascularity. The capillary-venous malformation typically fills the subarachnoid space in the sulci, and large tortuous venous structures most commonly drain into the deep venous system, but may also drain into superficial veins. The underlying parenchyma may be atrophic and contain multiple calcific granular deposits. The intraparenchymal calcification is the result of chronic tissue ischemia caused by venous stasis, a phenomenon known as dystrophic calcification.",
"   </p>",
"   <p>",
"    There is evidence that the leptomeningeal capillary-venous malformations in SWS are not static lesions but rather undergo angiogenic remodeling. In one study, the abnormal tissue vessels showed an increased expression of VEGF, VEGF receptors, and angiopoietin receptor TIE2 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4727/abstract/12\">",
"     12",
"    </a>",
"    ]. These findings may lead to the development of new therapeutic strategies in SWS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seizures occurred in 80 percent of patients with SWS in one series and were more common with bilateral than unilateral port wine stains (87 versus 71 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4727/abstract/13\">",
"     13",
"    </a>",
"    ]. In another report, seizures occurred in 93 percent of patients with bilateral leptomeningeal lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4727/abstract/14\">",
"     14",
"    </a>",
"    ]. In one case series of six patients with SWS who underwent epilepsy surgery, pathologic examination in all patients revealed a cortical malformation (polymicrogyria, cortical dysplasia) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4727/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Seizures in SWS may develop at any age, although they usually start in early childhood. In one study of 171 patients with SWS, seizures began by one, two, and five years of age in 75, 86, and 95 percent of affected patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4727/abstract/13\">",
"     13",
"    </a>",
"    ]. In another report of 77 children and adults with SWS and at least one witnessed seizure, the median age of seizure onset was six months [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4727/abstract/16\">",
"     16",
"    </a>",
"    ]. A pattern of severe seizures occurring in clusters was noted in 30 patients (39 percent). In patients with this pattern, seizures occurred in clusters of 1 to 21 (median 5) over a period of 1 to 10 days (median 2).",
"   </p>",
"   <p>",
"    Seizures are often the first symptom of SWS. They may occur in the setting of an acute illness and may be associated with the acute onset of hemiparesis. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Hemiparesis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Initially, seizures are typically focal, but often become generalized tonic-clonic. Less often, infantile spasms or myoclonic or atonic seizures are seen.",
"   </p>",
"   <p>",
"    The success of controlling seizures with anticonvulsant medication is variable and unpredictable. Some patients have long intervals without seizures, even without medication, while others have frequent or prolonged seizures despite high doses of multiple medications.",
"   </p>",
"   <p>",
"    The occurrence of seizures, the age at onset, and the response to treatment affect prognosis. Onset before one year and poor response to anticonvulsant therapy are associated with a greater likelihood of cognitive impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4727/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hemiparesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemiparesis often develops acutely in conjunction with the onset of seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4727/abstract/3\">",
"     3",
"    </a>",
"    ]. The deficit occurs contralateral to the intracranial lesion. The paretic extremity usually does not grow at a normal rate, resulting in hemiatrophy.",
"   </p>",
"   <p>",
"    Some affected children have progressive loss of motor function or have a series of stroke-like events. The mechanism for this deterioration is uncertain. Possible mechanisms include a cumulative effect of repeated thrombotic events within the leptomeningeal capillary-venous malformation or chronic disturbance of blood flow and oxygen delivery to the involved tissues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Intellectual disability (mental retardation)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with SWS typically develop normally for several months after birth, then manifest developmental delay. However, impairment can be obvious soon after birth, especially in infants with extensive brain involvement.",
"   </p>",
"   <p>",
"    In one report, mental retardation occurred in 60 percent of patients and was severe in 33 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4727/abstract/17\">",
"     17",
"    </a>",
"    ]. In another study, mental handicap occurred in approximately one-half of affected adults [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4727/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cognitive function is poorest in patients with bilateral intracerebral lesions. In one report of 122 patients with SWS, only 8 percent of patients with bilateral leptomeningeal capillary-venous malformations were intellectually normal [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4727/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Behavioral problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Behavioral problems are more common in children with SWS than in their unaffected siblings [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4727/abstract/19\">",
"     19",
"    </a>",
"    ]. The risk for behavioral problems is associated with poorer cognitive function and the presence of epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4727/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. However, behavioral problems can occur in patients with normal intelligence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Visual field defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients have visual field defects, typically a homonymous hemianopia. This is due to the presence of a leptomeningeal affecting one or both occipital lobes or optic tracts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/61/37848?source=see_link\">",
"     \"Homonymous hemianopia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H941379\">",
"    <span class=\"h2\">",
"     Glaucoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The predominant ocular abnormality of SWS is glaucoma (increased intraocular pressure), which occurs in 30 to 70 percent of affected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4727/abstract/7,21\">",
"     7,21",
"    </a>",
"    ]. The risk of glaucoma is highest in the first decade. Congenital glaucoma is seen in approximately one-half of patients with SWS and presents in newborns with enlargement of the globe (buphthalmos). Occasional patients develop glaucoma as adults. Thus, continued vigilance is needed, even in patients with initially normal intraocular pressure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41463?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of glaucoma in infants and children\", section on 'Sturge-Weber syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H941386\">",
"    <span class=\"h2\">",
"     Other ophthalmologic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other ophthalmologic complications include vascular anomalies, heterochromia of the iris, and visual field defects [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4727/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Capillary-venous malformation of the choroid (also known as choroidal hemangioma) occurs in 30 to 40 percent of patients with SWS and can lead to increased intraocular pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?4/39/4727/abstract/7,21,22\">",
"       7,21,22",
"      </a>",
"      ]. These lesions may be diffuse or localized within the retina (",
"      <a class=\"graphic graphic_picture graphicRef74289 \" href=\"UTD.htm?39/29/40400\">",
"       picture 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Episcleral and conjunctival lesions include anomalous vessels or capillary-venous malformations [",
"      <a class=\"abstract\" href=\"UTD.htm?4/39/4727/abstract/23\">",
"       23",
"      </a>",
"      ]. In a series of 51 children with SWS, episcleral or conjunctival hemangiomas occurred in 69 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?4/39/4727/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Heterochromia of the iris originally was noted by Weber. The more deeply pigmented iris usually is ipsilateral to the facial angioma. The pigmentation is caused by aggregated melanocytic hamartomata on the anterior surface of the iris.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H941075\">",
"    <span class=\"h2\">",
"     Neuroendocrine aspects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of growth hormone deficiency in SWS is increased up to 18-fold compared with the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4727/abstract/24\">",
"     24",
"    </a>",
"    ]. Growth hormone deficiency occurs without neuroimaging evidence of pituitary or hypothalamic abnormalities. Central hypothyroidism has also been reported in SWS [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4727/abstract/25\">",
"     25",
"    </a>",
"    ]. Since both of these conditions can be effectively treated, appropriate screening tests should be obtained if indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of SWS is based upon demonstration of the facial capillary malformations and leptomeningeal capillary-venous malformations. Occasional patients who have the leptomeningeal lesion but no facial lesion are identified when neurologic problems develop. These patients also may have glaucoma or other ocular features of the disorder.",
"   </p>",
"   <p>",
"    SWS should be distinguished from Klippel-Trenaunay syndrome. In the latter, extensive capillary malformations associated with dysplastic veins involve the limbs and trunk, often with hypertrophy of the affected extremity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preferred neuroimaging technique for the diagnosis of SWS is brain MRI with gadolinium contrast, which demonstrates the presence of the leptomeningeal capillary-venous malformation and the extent of involvement with brain structures (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57902 graphicRef59833 graphicRef63073 \" href=\"UTD.htm?6/30/6634\">",
"     image 1A-C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4727/abstract/26\">",
"     26",
"    </a>",
"    ]. In some cases, leptomeningeal involvement may not be detected by neuroimaging during infancy and becomes apparent later [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4727/abstract/1\">",
"     1",
"    </a>",
"    ]. There is a general consensus among experts that a negative brain MRI with gadolinium at one year of age can reliably exclude the presence of a leptomeningeal lesion. If MRI is not available, cranial computed tomography can identify brain calcification and provide some anatomic information.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 90 percent of infants with facial port wine stains do not have an intracranial lesion and would be expected to develop normally. However, SWS cannot be ruled out by a normal brain MRI in the first few months of life. Given these data, and the need to sedate infants for MRI, it is reasonable to perform imaging in infancy only if specific ocular and neurologic abnormalities (glaucoma, seizures, or hemiparesis) are present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;No specific treatment exists for SWS. The cutaneous, ocular, and neurologic manifestations are treated with mixed success. There is increasing agreement among experienced clinicians that low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    may be beneficial, with the rationale that antithrombotic therapy may prevent the progression of impaired cerebral blood flow and hypoxic-ischemic neuronal injury [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4727/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. However, no controlled studies exist. There is no increased risk of intracranial hemorrhage in patients with SWS whether on aspirin or not.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Cutaneous lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Port wine stains can be treated by selective photothermolysis using a pulsed dye laser. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/47/17146?source=see_link&amp;anchor=H10061356#H10061356\">",
"     \"Laser and light therapy for cutaneous vascular lesions\", section on 'Port wine stains'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Glaucoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of topical medications has improved the medical management of glaucoma in SWS [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4727/abstract/8\">",
"     8",
"    </a>",
"    ]. However, topical treatment often is ineffective in normalizing intraocular pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4727/abstract/31\">",
"     31",
"    </a>",
"    ]. In these cases, the surgical treatment depends upon the etiology of the glaucoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41463?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of glaucoma in infants and children\", section on 'Sturge-Weber syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of seizures in SWS often is difficult. In one report, adequate control was accomplished with anticonvulsant therapy in approximately 40 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4727/abstract/32\">",
"     32",
"    </a>",
"    ]. In refractory cases, hemispherectomy or more limited surgical resection of epileptogenic tissue may be beneficial, although data are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4727/abstract/33-36\">",
"     33-36",
"    </a>",
"    ]. The available data suggest that focal resections are less likely to result in good seizure control than hemispherectomy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a survey of 70 patients identified by the Sturge-Weber Foundation who had a hemispherectomy between 1979 and 2001, 81 percent of the 32 who responded were free of seizures and 53 percent were off anticonvulsants [",
"      <a class=\"abstract\" href=\"UTD.htm?4/39/4727/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective review of 27 children with SWS who had surgery for medically resistant epilepsy, functional or anatomic hemispherectomy was followed by complete resolution of seizures in eight of eight patients; with focal resection, seizure-free outcome was reported of 11 of 19 (58 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/39/4727/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, some experts recommend surgery with hemispherectomy, lobectomy or transection of the corpus callosum for patients with SWS and medically resistant epilepsy (eg, poor seizure control despite treatment for six months with a minimum of two anticonvulsants), particularly when associated with clinically significant hemiparesis, visual field loss, and developmental delay [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4727/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis for SWS depends upon the extent of the leptomeningeal capillary-venous malformation and its effect on the perfusion of the cerebral cortex, as well as the severity of ocular involvement. Prognosis also is affected by the age of onset of seizures and whether they can be controlled.",
"   </p>",
"   <p>",
"    Neurologic function may deteriorate with age. As a result, approximately one-half of affected adults are impaired, including those who initially were normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35507872\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sturge-Weber syndrome (SWS) is a rare congenital vascular disorder that affects capillary size blood vessels. It is not a heritable disorder. SWS is characterized by facial capillary malformation (port wine stain) and associated capillary-venous malformations affecting the brain and eye. These vascular malformations are associated with specific ocular and neurologic abnormalities. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cutaneous port wine stain is the most common type of vascular malformation, occurring in 0.3 percent of newborn infants (",
"      <a class=\"graphic graphic_picture graphicRef73343 \" href=\"UTD.htm?1/61/2002\">",
"       picture 1",
"      </a>",
"      ). However, only a small proportion of children with port wine stains have SWS. The port wine stain of SWS typically is present on the forehead and upper eyelid, primarily in the distribution of the first or second division of the trigeminal nerve. Although traditionally considered important in determining meningeal involvement risk, the location of the port wine stain on the face is not a good indicator of the risk of an underlying meningeal capillary malformation. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Port wine stain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A leptomeningeal capillary-venous malformation (angioma) occurs in 10 to 20 percent of cases when a typical facial lesion is present. The intracerebral lesion usually occurs on the same side as the port wine stain. The parietal and occipital areas are affected most commonly. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Leptomeningeal vascular malformation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ocular features of SWS include glaucoma, vascular malformations of the conjunctiva, episclera, choroid (",
"      <a class=\"graphic graphic_picture graphicRef74289 \" href=\"UTD.htm?39/29/40400\">",
"       picture 3",
"      </a>",
"      ) and retina, and heterochromia of the iris. (See",
"      <a class=\"local\" href=\"#H941379\">",
"       'Glaucoma'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H941386\">",
"       'Other ophthalmologic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The neurologic features of SWS may be progressive and include seizures, focal neurologic deficits, visual field defects, and mental retardation. These disorders occur with variable severity. A small proportion of patients have no neurologic abnormalities. Seizures in SWS may develop at any age, although they usually start in early childhood. Hemiparesis often develops acutely in conjunction with the onset of seizures. Some affected children have progressive loss of motor function or have a series of stroke-like events. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Seizures'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Hemiparesis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Intellectual disability (mental retardation)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Behavioral problems'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Visual field defects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of SWS is based upon demonstration of the facial and leptomeningeal vascular malformations. Occasional patients who have the leptomeningeal capillary-venous malformation but no facial lesion are identified when neurologic problems develop. SWS should be distinguished from Klippel-Trenaunay-Weber syndrome in which extensive capillary angiomata associated with dysplastic veins involve the limbs and trunk, often with hypertrophy of the affected extremity. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The preferred diagnostic neuroimaging technique for SWS is brain MRI with gadolinium contrast, which demonstrates the presence of the leptomeningeal capillary-venous malformation and the extent of involvement with brain structures (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef57902 graphicRef59833 graphicRef63073 \" href=\"UTD.htm?6/30/6634\">",
"       image 1A-C",
"      </a>",
"      ). A negative brain MRI with gadolinium at one year of age can reliably exclude the presence of leptomeningeal lesion. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Neuroimaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No specific treatment exists for SWS. The cutaneous, ocular, and neurologic manifestations are managed with mixed success. There is increasing agreement among experienced clinicians that low dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      may be beneficial, though no controlled studies exist. There is no increased risk of intracranial hemorrhage in patients with SWS whether on aspirin or not. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4727/abstract/1\">",
"      Comi AM. Presentation, diagnosis, pathophysiology, and treatment of the neurological features of Sturge-Weber syndrome. Neurologist 2011; 17:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4727/abstract/2\">",
"      Happle R. Lethal genes surviving by mosaicism: a possible explanation for sporadic birth defects involving the skin. J Am Acad Dermatol 1987; 16:899.",
"     </a>",
"    </li>",
"    <li>",
"     Bodensteiner JB, Roach ES. Sturge-Weber syndrome: Introduction and overview. In: Sturge-Weber Syndrome, 2nd edition, Bodensteiner JB, Roach ES (Eds), Sturge-Weber Foundation, Mt. Freedom, NJ 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4727/abstract/4\">",
"      Fishman MA, Baram TZ. Megalencephaly due to impaired cerebral venous return in a Sturge-Weber variant syndrome. J Child Neurol 1986; 1:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4727/abstract/5\">",
"      Maria BL, Neufeld JA, Rosainz LC, et al. Central nervous system structure and function in Sturge-Weber syndrome: evidence of neurologic and radiologic progression. J Child Neurol 1998; 13:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4727/abstract/6\">",
"      Lee JS, Asano E, Muzik O, et al. Sturge-Weber syndrome: correlation between clinical course and FDG PET findings. Neurology 2001; 57:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4727/abstract/7\">",
"      Sullivan TJ, Clarke MP, Morin JD. The ocular manifestations of the Sturge-Weber syndrome. J Pediatr Ophthalmol Strabismus 1992; 29:349.",
"     </a>",
"    </li>",
"    <li>",
"     Cheng KP. Ophthalmologic manifestations of Sturge-Weber syndrome. In: Sturge-Weber Syndrome, Bodensteiner JB, Roach ES (Eds), Sturge-Weber Foundation, Mt. Freedom, NJ 1999. p.17.",
"    </li>",
"    <li>",
"     Bodensteiner JB. Sturge-Weber Syndrome. In: Vascular Birthmarks of the Head and Neck, Hochman M (Ed), Facial Plastic Surgery Clinics of North America, 2001. p.569.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4727/abstract/10\">",
"      Tallman B, Tan OT, Morelli JG, et al. Location of port-wine stains and the likelihood of ophthalmic and/or central nervous system complications. Pediatrics 1991; 87:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4727/abstract/11\">",
"      Aydin A, Cakmak&ccedil;i H, Kovanlikaya A, Dirik E. Sturge-Weber syndrome without facial nevus. Pediatr Neurol 2000; 22:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4727/abstract/12\">",
"      Comati A, Beck H, Halliday W, et al. Upregulation of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha in leptomeningeal vascular malformations of Sturge-Weber syndrome. J Neuropathol Exp Neurol 2007; 66:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4727/abstract/13\">",
"      Sujansky E, Conradi S. Sturge-Weber syndrome: age of onset of seizures and glaucoma and the prognosis for affected children. J Child Neurol 1995; 10:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4727/abstract/14\">",
"      Bebin EM, Gomez MR. Prognosis in Sturge-Weber disease: comparison of unihemispheric and bihemispheric involvement. J Child Neurol 1988; 3:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4727/abstract/15\">",
"      Maton B, Krsek P, Jayakar P, et al. Medically intractable epilepsy in Sturge-Weber syndrome is associated with cortical malformation: implications for surgical therapy. Epilepsia 2010; 51:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4727/abstract/16\">",
"      Kossoff EH, Ferenc L, Comi AM. An infantile-onset, severe, yet sporadic seizure pattern is common in Sturge-Weber syndrome. Epilepsia 2009; 50:2154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4727/abstract/17\">",
"      Pascual-Castroviejo I, D&iacute;az-Gonzalez C, Garc&iacute;a-Melian RM, et al. Sturge-Weber syndrome: study of 40 patients. Pediatr Neurol 1993; 9:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4727/abstract/18\">",
"      Sujansky E, Conradi S. Outcome of Sturge-Weber syndrome in 52 adults. Am J Med Genet 1995; 57:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4727/abstract/19\">",
"      Chapieski L, Friedman A, Lachar D. Psychological functioning in children and adolescents with Sturge-Weber syndrome. J Child Neurol 2000; 15:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4727/abstract/20\">",
"      Raches D, Hiscock M, Chapieski L. Behavioral and academic problems in children with Sturge-Weber syndrome: differences between children with and without seizures. Epilepsy Behav 2012; 25:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4727/abstract/21\">",
"      Baselga E. Sturge-Weber syndrome. Semin Cutan Med Surg 2004; 23:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4727/abstract/22\">",
"      Singh AD, Kaiser PK, Sears JE. Choroidal hemangioma. Ophthalmol Clin North Am 2005; 18:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4727/abstract/23\">",
"      Phelps CD. The pathogenesis of glaucoma in Sturge-Weber syndrome. Ophthalmology 1978; 85:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4727/abstract/24\">",
"      Miller RS, Ball KL, Comi AM, Germain-Lee EL. Growth hormone deficiency in Sturge-Weber syndrome. Arch Dis Child 2006; 91:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4727/abstract/25\">",
"      Comi AM, Bellamkonda S, Ferenc LM, et al. Central hypothyroidism and Sturge-Weber syndrome. Pediatr Neurol 2008; 39:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4727/abstract/26\">",
"      Truhan AP, Filipek PA. Magnetic resonance imaging. Its role in the neuroradiologic evaluation of neurofibromatosis, tuberous sclerosis, and Sturge-Weber syndrome. Arch Dermatol 1993; 129:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4727/abstract/27\">",
"      Comi AM. Update on Sturge-Weber syndrome: diagnosis, treatment, quantitative measures, and controversies. Lymphat Res Biol 2007; 5:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4727/abstract/28\">",
"      Puttgen KB, Lin DD. Neurocutaneous vascular syndromes. Childs Nerv Syst 2010; 26:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4727/abstract/29\">",
"      Bay MJ, Kossoff EH, Lehmann CU, et al. Survey of aspirin use in Sturge-Weber syndrome. J Child Neurol 2011; 26:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4727/abstract/30\">",
"      Lance EI, Sreenivasan AK, Zabel TA, et al. Aspirin use in Sturge-Weber syndrome: side effects and clinical outcomes. J Child Neurol 2013; 28:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4727/abstract/31\">",
"      van Emelen C, Goethals M, Dralands L, Casteels I. Treatment of glaucoma in children with Sturge-Weber syndrome. J Pediatr Ophthalmol Strabismus 2000; 37:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4727/abstract/32\">",
"      Arzimanoglou A, Aicardi J. The epilepsy of Sturge-Weber syndrome: clinical features and treatment in 23 patients. Acta Neurol Scand Suppl 1992; 140:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4727/abstract/33\">",
"      Arzimanoglou AA, Andermann F, Aicardi J, et al. Sturge-Weber syndrome: indications and results of surgery in 20 patients. Neurology 2000; 55:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4727/abstract/34\">",
"      Vining EP, Freeman JM, Pillas DJ, et al. Why would you remove half a brain? The outcome of 58 children after hemispherectomy-the Johns Hopkins experience: 1968 to 1996. Pediatrics 1997; 100:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4727/abstract/35\">",
"      Kossoff EH, Buck C, Freeman JM. Outcomes of 32 hemispherectomies for Sturge-Weber syndrome worldwide. Neurology 2002; 59:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4727/abstract/36\">",
"      Bourgeois M, Crimmins DW, de Oliveira RS, et al. Surgical treatment of epilepsy in Sturge-Weber syndrome in children. J Neurosurg 2007; 106:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4727/abstract/37\">",
"      Comi AM. Sturge-Weber syndrome and epilepsy: an argument for aggressive seizure management in these patients. Expert Rev Neurother 2007; 7:951.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6159 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-7AD06D259D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_39_4727=[""].join("\n");
var outline_f4_39_4727=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H35507872\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Port wine stain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Leptomeningeal vascular malformation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hemiparesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Intellectual disability (mental retardation)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Behavioral problems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Visual field defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H941379\">",
"      Glaucoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H941386\">",
"      Other ophthalmologic findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H941075\">",
"      Neuroendocrine aspects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Cutaneous lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Glaucoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Seizures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35507872\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6159\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6159|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/24/19843\" title=\"diagnostic image 1A\">",
"      Axial MRI Sturge-Weber",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/47/1778\" title=\"diagnostic image 1B\">",
"      Sagittal MRI Sturge-Weber",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?5/39/5747\" title=\"diagnostic image 1C\">",
"      Coronal axial MRI Sturge-Weber",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6159|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/61/2002\" title=\"picture 1\">",
"      Bilateral port wine stains in SWS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/53/22367\" title=\"picture 2\">",
"      Adult with SWS and port wine stain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/29/40400\" title=\"picture 3\">",
"      Diffuse choroidal hemangioma in SWS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/61/37848?source=related_link\">",
"      Homonymous hemianopia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/47/17146?source=related_link\">",
"      Laser and light therapy for cutaneous vascular lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41463?source=related_link\">",
"      Overview of glaucoma in infants and children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_39_4728="Ziprasidone: Drug information";
var content_f4_39_4728=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ziprasidone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?21/5/21590?source=see_link\">",
"    see \"Ziprasidone: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/33/23064?source=see_link\">",
"    see \"Ziprasidone: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F235894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Geodon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5498099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Zeldox&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F235918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antipsychotic Agent, Atypical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F235897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bipolar mania (acute):",
"     </b>",
"     Oral: Initial: 40 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Adjustment:",
"     </i>",
"     May increase to 60 mg or 80 mg twice daily on second day of treatment; average dose 40-80 mg twice daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bipolar disorder (maintenance; as adjunct to lithium or valproate):",
"     </b>",
"     Oral: Continue ziprasidone dose at which the patient was initially stabilized; usual dosage range: 40-80 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Schizophrenia:",
"     </b>",
"     Oral: Initial: 20 mg twice daily (U.S. labeling) or 20-40 mg twice daily (Canadian labeling)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Adjustment:",
"     </i>",
"     Increases (if indicated) should be made no more frequently than every 2 days; ordinarily patients should be observed for improvement over several weeks before adjusting the dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Maintenance:",
"     </i>",
"     Range: 20-100 mg twice daily; however, dosages &gt;80 mg twice daily are generally not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute agitation (schizophrenia):",
"     </b>",
"     I.M.: 10 mg every 2 hours",
"     <b>",
"      or",
"     </b>",
"     20 mg every 4 hours (maximum: 40 mg/day). Oral therapy should replace I.M. administration as soon as possible.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F235908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/33/23064?source=see_link\">",
"      see \"Ziprasidone: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tourette's syndrome (unlabeled use; Sallee, 2000):",
"     </b>",
"     Children and adolescents: Oral: 5-40 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F235898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment is recommended; consider initiating at a low end of the dosage range, with slower titration.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F235899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: No dosage adjustment is recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.: Cyclodextrin, an excipient in the I.M. formulation, is cleared by renal filtration; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ziprasidone is not removed by hemodialysis.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F235900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     U.S. labeling: No dosage adjustment is recommended; however, drug undergoes extensive hepatic metabolism and systemic exposure may be increased.  Use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Canadian labeling: Manufacturer labeling suggests that dose reductions should be considered but does not provide specific dosing recommendations.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F235867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as hydrochloride: 20 mg, 40 mg, 60 mg, 80 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Geodon&reg;: 20 mg, 40 mg, 60 mg, 80 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as mesylate [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Geodon&reg;: 20 mg [contains cyclodextrin]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F235853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Capsule",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F235870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer with food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection: For I.M. administration only.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F235868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of schizophrenia; treatment of acute manic or mixed episodes associated with bipolar disorder with or without psychosis; maintenance treatment of bipolar disorder as an adjunct to lithium or valproate; acute agitation in patients with schizophrenia",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F235914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tourette's syndrome; psychosis/agitation related to Alzheimer's dementia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F10524190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ziprasidone may be confused with TraZODone",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F235916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Although minor QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation (mean: 10 msec at 160 mg/day) may occur more frequently (incidence not specified), clinically-relevant prolongation (&gt;500 msec) was rare (0.06%) and less than placebo (0.23%).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Extrapyramidal symptoms (2% to 31%), somnolence (8% to 31%), headache (3% to 18%), dizziness (3% to 16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (4% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Orthostatic hypotension (5%), chest pain (3%), hypertension (2% to 3%), tachycardia (2%), bradycardia (&le;2%), facial edema (1%), vasodilation (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Akathisia (2% to 10%), anxiety (2% to 5%), insomnia (3%), agitation (2%), speech disorder (2%), personality disorder (2%), akinesia (&ge;1%), amnesia (&ge;1%), ataxia (&ge;1%), confusion (&ge;1%), coordination abnormal (&ge;1%), delirium (&ge;1%), dystonia (&ge;1%), hostility (&ge;1%), oculogyric crisis (&ge;1%), vertigo (&ge;1%), chills (1%), fever (1%), hypothermia (1%), psychosis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (4% to 5%), fungal dermatitis (2%), photosensitivity reaction (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dysmenorrhea (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Weight gain (6% to 10%), constipation (2% to 9%), dyspepsia (1% to 8%), diarrhea (3% to 5%), vomiting (3% to 5%), xerostomia (1% to 5%), salivation increased (4%), tongue edema (&le;3%), anorexia (2%), abdominal pain (&le;2%), dysphagia (&le;2%), rectal hemorrhage (&le;2%), buccoglossal syndrome (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Priapism (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site pain (7% to 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (2% to 6%), hypoesthesia (2%), myalgia (2%), paresthesia (2%), abnormal gait (&ge;1%), choreoathetosis (&ge;1%), dysarthria (&ge;1%), dyskinesia (&ge;1%), hyper-/hypokinesia (&ge;1%), hypotonia (&ge;1%), neuropathy (&ge;1%), tremor (&ge;1%), twitching (&ge;1%), back pain (1%), cogwheel rigidity (1%), hypertonia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Vision abnormal (3% to 6%), diplopia (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Infection (8%), rhinitis (1% to 4%), cough (3%), pharyngitis (3%), dyspnea (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (2%), furunculosis (2%), withdrawal syndrome (&ge;1%), flank pain (1%), flu-like syndrome (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abnormal ejaculation, albuminuria, alkaline phosphatase increased, allergic reaction, alopecia, amenorrhea, anemia, angioedema, angina, anorgasmia, atrial fibrillation, AV block (first degree), basophilia, blepharitis, bruising, BUN increased, bundle branch block, cardiomegaly, cataract, cerebral infarction, cerebrovascular accident, cholestatic jaundice, circumoral paresthesia, conjunctivitis, contact dermatitis, CPK increased, creatinine (serum) increased, dehydration, depression, dry eyes, eczema, enuresis, eosinophilia, epistaxis, exfoliative dermatitis, facial droop, fatty liver, fecal impaction, galactorrhea, GGT increased, gingival bleeding, glycosuria, gout, gynecomastia, hematemesis, hemoptysis, hematuria, hepatitis, hepatomegaly, hyper-/hypochloremia, hyper-/hypocholesterolemia, hyper-/hypoglycemia, hyper-/hypokalemia, hyper-/hypothyroidism, hyperlipemia, hyper-reflexia, hyperuricemia, hypocalcemia, hypomagnesemia, hyponatremia, hypoproteinemia, impotence, jaundice, keratitis, keratoconjunctivitis, ketosis, lactation (female), laryngismus, LDH increased, leukocytosis, leukopenia, leukoplakia (mouth), lymphadenopathy, lymphedema, lymphocytosis, maculopapular rash, mania/hypomania, melena, menorrhagia, metrorrhagia, monocytosis, myocarditis, myoclonus, myopathy, neuroleptic malignant syndrome, nocturia, nystagmus, ocular hemorrhage, oliguria, opisthotonos, paralysis, peripheral edema, phlebitis, photophobia, pneumonia, polycythemia, polyuria, pulmonary embolism, QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation &gt;500 msec, respiratory alkalosis, seizure, serotonin syndrome, sexual dysfunction (male and female), syncope, tardive dyskinesia, tenosynovitis, thirst, thrombocytopenia, thrombocythemia, thrombophlebitis, thyroiditis, tinnitus, torsade de pointes, torticollis, transaminases increased, trismus, urinary incontinence, urinary retention, urticaria, uterine hemorrhage, vaginal hemorrhage, vesiculobullous rash, visual field defect",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F235873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ziprasidone or any component of the formulation; history of (or current) prolonged QT; congenital long QT syndrome; recent myocardial infarction;  uncompensated heart failure; concurrent use of other QT",
"     <sub>",
"      c",
"     </sub>",
"     -prolonging agents including arsenic trioxide, chlorpromazine, class Ia antiarrhythmics (eg, disopyramide, quinidine, procainamide), class III antiarrhythmics (eg, amiodarone, dofetilide, ibutilide, sotalol), dolasetron, droperidol, gatifloxacin, levomethadyl, mefloquine, mesoridazine, moxifloxacin, pentamidine, pimozide, probucol, tacrolimus, and thioridazine",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F235857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood dyscrasias: Leukopenia, neutropenia, and agranulocytosis (sometimes fatal) have been reported in clinical trials and postmarketing reports with antipsychotic use; presence of risk factors (eg, pre-existing low WBC or history of drug-induced leuko-/neutropenia) should prompt periodic blood count assessment. Discontinue therapy at first signs of blood dyscrasias or if absolute neutrophil count &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Esophageal dysmotility/aspiration: Antipsychotic use has been associated with esophageal dysmotility and aspiration; use with caution in patients at risk of pneumonia (ie, Alzheimer's disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extrapyramidal symptoms (EPS): May cause extrapyramidal symptoms, including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia (risk of these reactions is generally much lower relative to typical/conventional antipsychotics). Risk of dystonia (and probably other EPS) may be greater with increased doses, use of conventional antipsychotics, males, and younger patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperglycemia: Atypical antipsychotics have been associated with development of hyperglycemia; in some cases, may be extreme and associated with ketoacidosis, hyperosmolar coma, or death. Use with caution in patients with diabetes or other disorders of glucose regulation; monitor for worsening of glucose control. There is limited documentation with ziprasidone and specific risk associated with this agent is not known.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperprolactinemia: May increase prolactin levels; clinical significance of hyperprolactinemia in patients with breast cancer or other prolactin-dependent tumors is unknown.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuroleptic malignant syndrome (NMS): Use may  be associated with neuroleptic malignant syndrome (NMS); monitor for mental status changes, fever, muscle rigidity and/or autonomic instability.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension; use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Priapism: Rare cases of priapism have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; QT prolongation: May result in QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation (dose related), which has been associated with the development of malignant ventricular arrhythmias (torsade de pointes) and sudden death. Observed prolongation was greater than with other atypical antipsychotic agents (risperidone, olanzapine, quetiapine), but less than with thioridazine. Avoid hypokalemia, hypomagnesemia. Use caution in patients with bradycardia. Discontinue in patients found to have persistent QT",
"     <sub>",
"      c",
"     </sub>",
"     intervals &gt;500 msec. Patients with symptoms of dizziness, palpitations, or syncope should receive further cardiac evaluation. Also see Contraindications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rash: Use has been associated with a fairly high incidence of rash (5%); discontinue if alternative etiology is not identified.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedation: Moderate to highly sedating, use with caution in disorders where CNS depression is a feature; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal ideation: The possibility of a suicide attempt is inherent in psychotic illness or bipolar disorder; use with caution in high-risk patients during initiation of therapy. Prescriptions should be written for the smallest quantity consistent with good patient care.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Temperature regulation: Impaired core body temperature regulation may occur; caution with strenuous exercise, heat exposure, dehydration, and concomitant medication possessing anticholinergic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Weight gain: Significant weight gain has been observed with antipsychotic therapy; incidence varies with product. Monitor waist circumference and BMI.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use is contraindicated in patients with recent acute myocardial infarction (MI), QT prolongation, or uncompensated heart failure.  Avoid use in patients with a history of cardiac arrhythmias; use with caution  in patients with history of MI or unstable heart disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dementia:",
"     <b>",
"      [U.S. Boxed Warning]: Elderly patients with dementia-related behavioral disorders treated with antipsychotics are at an increased risk of death compared to placebo.",
"     </b>",
"     Most deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. Ziprasidone is not approved for the treatment of dementia-related psychosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte imbalance: Correct electrolyte disturbances, especially hypokalemia or hypomagnesemia, prior to use and throughout therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic disease or impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Parkinson's disease: Use with caution in patients with Parkinson's disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use the intramuscular formulation with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold. Elderly patients may be at increased risk of seizures due to an increased prevalence of predisposing factors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly:  Use in patients with dementia is associated with an increased risk of mortality and cerebrovascular accidents; avoid antipsychotic use for behavioral problems associated with dementia unless alternative nonpharmacologic therapies have failed and patient may harm self or others. In addition, use may cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Intramuscular formulation: Use the intramuscular formulation with caution in patients with renal impairment; formulation contains cyclodextrin, an excipient which may accumulate in renal insufficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F235911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F235861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): May enhance the neurotoxic (central) effect of Antipsychotics. Severe extrapyramidal symptoms have occurred in some patients.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antipsychotics may diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Ziprasidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anti-Parkinson's Agents (Dopamine Agonist): Antipsychotics (Atypical) may diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist).  Management: Consider using an alternative antipsychotic agent when possible in patients with Parkinson's disease.  If an atypical antipsychotic is necessary, consider using clozapine or quetiapine, which may convey the lowest interaction risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Ziprasidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium formulations: May enhance the neurotoxic effect of Antipsychotics. Lithium formulations may decrease the serum concentration of Antipsychotics. Specifically noted with chlorpromazine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antipsychotics may enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinagolide: Antipsychotics may diminish the therapeutic effect of Quinagolide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: Antipsychotics may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F235889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Administration with food increases serum levels twofold. Grapefruit juice may increase serum concentration of ziprasidone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease serum levels of ziprasidone, due to a potential effect on CYP3A4. This has not been specifically studied. Avoid kava kava, chamomile (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F235863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F235877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Developmental toxicity demonstrated in animals. Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms [EPS]) and withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor; these effects may be self-limiting or require hospitalization. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies risk to the fetus. Healthcare providers are encouraged to enroll women 18-45 years of age exposed to ziprasidone during pregnancy in the Atypical Antipsychotics Pregnancy Registry (1-866-961-2388 or file://www.womensmentalhealth.org/pregnancyregistry).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F235904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9626986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take with food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F235876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Geodon Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (60): $651.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (60): $651.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg (60): $790.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg (60): $790.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Ziprasidone HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (60): $531.83",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (60): $531.83",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg (60): $645.41",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg (60): $645.41",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Geodon Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (1): $22.06",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F235865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, heart rate; temperature; serum potassium and magnesium; fasting lipid profile and fasting blood glucose/Hgb A",
"     <sub>",
"      1c",
"     </sub>",
"     (prior to treatment, at 3 months, then annually); BMI; waist circumference; mental status, abnormal involuntary movement scale (AIMS), extrapyramidal symptoms. Weight should be assessed prior to treatment, at 4 weeks, 8 weeks, 12 weeks, and then at quarterly intervals. Consider titrating to a different antipsychotic agent for a weight gain &ge;5% of the initial weight. The value of routine ECG screening or monitoring has not been established.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F2869441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Azona (IN);",
"     </li>",
"     <li>",
"      Geodon (BR, BZ, CO, CR, DO, ES, GR, GT, HN, IE, IL, MX, NI, PA, SV, TW, VE, ZA);",
"     </li>",
"     <li>",
"      Zeldox (AR, AT, AU, BG, BR, CL, CN, CZ, DE, DK, EE, ES, FI, HK, MY, NO, NZ, PE, PH, PL, PT, RU, SE, SG, TH, UY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F235856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ziprasidone is a benzylisothiazolylpiperazine antipsychotic. The exact mechanism of action is unknown. However,",
"     <i>",
"      in vitro",
"     </i>",
"     radioligand studies show that ziprasidone has high affinity for D",
"     <sub>",
"      2",
"     </sub>",
"     , D",
"     <sub>",
"      3",
"     </sub>",
"     , 5-HT",
"     <sub>",
"      2A",
"     </sub>",
"     , 5-HT",
"     <sub>",
"      1A",
"     </sub>",
"     , 5-HT",
"     <sub>",
"      2C",
"     </sub>",
"     , 5-HT",
"     <sub>",
"      1D",
"     </sub>",
"     , and alpha",
"     <sub>",
"      1",
"     </sub>",
"     -adrenergic; moderate affinity for histamine H",
"     <sub>",
"      1",
"     </sub>",
"     receptors; and no appreciable affinity for alpha",
"     <sub>",
"      2",
"     </sub>",
"     -adrenergic receptors, beta-adrenergic, 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     , 5-HT",
"     <sub>",
"      4",
"     </sub>",
"     , cholinergic, mu, sigma, or benzodiazepine receptors. Ziprasidone functions as an antagonist at the D",
"     <sub>",
"      2",
"     </sub>",
"     , 5-HT",
"     <sub>",
"      2A",
"     </sub>",
"     , and 5-HT",
"     <sub>",
"      1D",
"     </sub>",
"     receptors and as an agonist at the 5-HT",
"     <sub>",
"      1A",
"     </sub>",
"     receptor. Ziprasidone moderately inhibits the reuptake of serotonin and norepinephrine.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F235872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 1.5 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;99%, primarily to albumin and alpha",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic, primarily via aldehyde oxidase; less than",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     of total metabolism via CYP3A4 and CYP1A2 (minor)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral (with food): 60% (up to twofold increase with food); I.M.: 100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 2-7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Oral: 6-8 hours; I.M.: &le;60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (~66%; &lt;4% of total dose as unchanged drug); urine (~20%; &lt;1% of total dose as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity, &ldquo;Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2004, 27(2):596-601.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/39/4728/abstract-text/14747245/pubmed\" id=\"14747245\" target=\"_blank\">",
"        14747245",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/39/4728/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Davis JM, Chen N, and Glick ID, &ldquo;A Meta-Analysis of the Efficacy of Second-Generation Antipsychotics,&rdquo;",
"      <i>",
"       Arch Gen Psychiatry",
"      </i>",
"      , 2003, 60(6):553-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/39/4728/abstract-text/12796218/pubmed\" id=\"12796218\" target=\"_blank\">",
"        12796218",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dixon L, Perkins D, and Calmes C,",
"      <i>",
"       Guideline Watch (September 2009): Practice Guideline for the Treatment of Schizophrenia",
"      </i>",
"      , Arlington, Va: American Psychiatric Association, 2009. Available at file://www.psychiatryonline.com/content.aspx?aid=501001.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gill SS, Bronskill SE, Normand SL, et al, &ldquo;Antipsychotic Drug Use and Mortality in Older Adults With Dementia,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2007, 146(11):775-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/39/4728/abstract-text/17548409/pubmed\" id=\"17548409\" target=\"_blank\">",
"        17548409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moore TA, &ldquo;Schizophrenia Treatment Guidelines in the United States,&rdquo;",
"      <i>",
"       Clin Schizophr Relat Psychoses",
"      </i>",
"      , 2011, 5(1):40-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/39/4728/abstract-text/21459738/pubmed\" id=\"21459738\" target=\"_blank\">",
"        21459738",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Health and Clinical Excellence (NICE), National Collaborating Centre for Mental Health , &ldquo;Schizophrenia. Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (Updated),&rdquo; National Clinical Practice Guideline Number 82, 2009:1-399. Available at  www.nice.org.uk/cg082",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rabins PV, Blacker D, Rovner BW, et al, &ldquo;American Psychiatric Association Practice Guideline for the Treatment of Patients With Alzheimer's Disease and Other Dementias. Second Edition,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2007, 164(12 Suppl):5-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/39/4728/abstract-text/18340692/pubmed\" id=\"18340692\" target=\"_blank\">",
"        18340692",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sallee FR, Kurlan R, Goetz CG, et al, &ldquo;Ziprasidone Treatment of Children and Adolescents With Tourette's Syndrome: A Pilot Study,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2000, 39(3):292-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/39/4728/abstract-text/10714048/pubmed\" id=\"10714048\" target=\"_blank\">",
"        10714048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schneeweiss S, Setoguchi S, Brookhart A, et al, &ldquo;Risk of Death Associated With the Use of Conventional Versus Atypical Antipsychotic Drugs Among Elderly Patients,&rdquo;",
"      <i>",
"       CMAJ",
"      </i>",
"      , 2007, 176(5): 627-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/39/4728/abstract-text/17325327/pubmed\" id=\"17325327\" target=\"_blank\">",
"        17325327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Suppes T, Dennehy EB, Hirschfeld RMA, et al, &ldquo;The Texas Implementation of Medication Algorithms: Update to the Algorithms for the Treatment of Bipolar I Disorder,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 2005, 66(7):870-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/39/4728/abstract-text/16013903/pubmed\" id=\"16013903\" target=\"_blank\">",
"        16013903",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10040 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-0E3ADE63EF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_39_4728=[""].join("\n");
var outline_f4_39_4728=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708843\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235894\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5498099\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235918\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235897\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235908\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235898\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235899\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235900\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235867\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235853\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235870\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235868\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235914\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10524190\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235916\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235873\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235857\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235911\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235861\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235889\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235863\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235877\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235904\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9626986\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235876\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235865\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2869441\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235856\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235872\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10040\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10040|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/5/21590?source=related_link\">",
"      Ziprasidone: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/33/23064?source=related_link\">",
"      Ziprasidone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_39_4729="Mechanical ventilation in neonates";
var content_f4_39_4729=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mechanical ventilation in neonates",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/39/4729/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/39/4729/contributors\">",
"     James M Adams, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/39/4729/contributors\">",
"     Eric C Eichenwald, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/39/4729/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/39/4729/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/39/4729/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/39/4729/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/39/4729/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The introduction of mechanical ventilation in the 1960s was one of the major new interventions in neonatology, which provided life-saving support for infants with respiratory failure. Over the past forty years, along with other technologic advancements such as the administration of antepartum corticosteroids and replacement surfactant therapy, mechanical ventilation has led to improved neonatal survival, especially for premature infants born less than 30 weeks gestation with immature lung function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14520?source=see_link\">",
"     \"Incidence and mortality of the premature infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although mechanical ventilation can be life saving, it may cause chronic lung injury that results in bronchopulmonary dysplasia (BPD), a major complication of prematurity. As a result, continued efforts have been focused upon development of new technology and strategies for neonatal ventilator care to maintain adequate gas exchange but minimize lung damage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18793?source=see_link\">",
"     \"Pathogenesis and clinical features of bronchopulmonary dysplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neonatal ventilator care, including the different types of mechanical ventilation and their advantages and disadvantages will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal benefits of neonatal mechanical ventilation during respiratory failure are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Improve gas exchange, primarily by lung recruitment to improve",
"      <span class=\"nowrap\">",
"       ventilation/perfusion",
"      </span>",
"      <span class=\"nowrap\">",
"       (V/Q)",
"      </span>",
"      matching (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26119?source=see_link&amp;anchor=H12#H12\">",
"       \"Physiologic and pathophysiologic consequences of mechanical ventilation\", section on 'Physiologic shunt'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Decrease work of breathing",
"     </li>",
"     <li>",
"      Provide ventilation in infants with respiratory depression or apnea",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Approximately two-thirds of all infants admitted to the neonatal intensive care unit (NICU) require positive pressure ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4729/abstract/1\">",
"     1",
"    </a>",
"    ]. Ventilation is commonly required for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Respiratory distress syndrome (RDS) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/34/43561?source=see_link&amp;anchor=H23056122#H23056122\">",
"       \"Prevention and treatment of respiratory distress syndrome in preterm infants\", section on 'Assisted ventilation techniques'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Apnea due to prematurity or perinatal anoxia",
"     </li>",
"     <li>",
"      Infection: sepsis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pneumonia",
"     </li>",
"     <li>",
"      Post-operative recovery",
"     </li>",
"     <li>",
"      Persistent pulmonary hypertension (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27225?source=see_link&amp;anchor=H17#H17\">",
"       \"Persistent pulmonary hypertension of the newborn\", section on 'Assisted ventilation'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Meconium aspiration syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18648?source=see_link&amp;anchor=H4#H4\">",
"       \"Prevention and management of meconium aspiration syndrome\", section on 'Assisted ventilation'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Congenital anomalies, such as congenital diaphragmatic hernia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28026?source=see_link&amp;anchor=H8#H8\">",
"       \"Congenital diaphragmatic hernia in the neonate\", section on 'Ventilation'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With the improvement in survival rate of very low birth weight infants (birth weight less than 1500 g), research efforts have been devoted to developing new ventilation strategies to reduce lung damage from positive pressure ventilation, in an attempt to decrease the incidence of BPD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4729/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18793?source=see_link&amp;anchor=H10#H10\">",
"     \"Pathogenesis and clinical features of bronchopulmonary dysplasia\", section on 'Mechanical ventilation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Indications for ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assisted ventilation should be initiated when respiratory failure occurs. Respiratory failure is verified by one of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Respiratory acidosis, documented by an arterial pH &lt;7.20 and a PaCO2 &gt;60 mm Hg",
"     </li>",
"     <li>",
"      Hypoxia, documented by an arterial PaO2 &lt;50 mm Hg despite oxygen supplementation of 70 percent on nasal CPAP",
"     </li>",
"     <li>",
"      Severe apnea",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Types of ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventilators used in the neonatal intensive care unit (NICU) can be divided into two categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Conventional ventilation or intermittent mandatory ventilation (IMV) is based upon setting a mandatory ventilator breath rate while continuous air flows through the ventilator circuit. The mode of mechanical ventilation refers to the method of setting the inspiratory support and time. As an example, during pressure-limited ventilation, inspiratory support ends after reaching the set inspiratory pressure, whereas in volume-targeted ventilation, inspiratory support ends after delivery of a set tidal volume. In some cases, support is terminated because a set time has elapsed. Ventilatory breaths may be triggered by the patient's own inspiratory effort, referred to as patient-triggered or synchronized ventilation.",
"     </li>",
"     <li>",
"      High frequency ventilation is based upon the delivery of small volumes of air, which are equal to or smaller than the anatomic dead space, at an extremely rapid rate (300 to 1500 breaths per minute).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CONVENTIONAL VENTILATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conventional ventilation (CV) or intermittent mandatory ventilation (IMV) delivers a set number of breaths per minute while gas flows continuously through the ventilator circuit allowing spontaneous breathing by the patient. The mode of mechanical ventilation and the duration of the inspiration are determined by setting pressure, volume, flow, or time parameters. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13336?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of mechanical ventilation\", section on 'Types of breaths'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43784?source=see_link\">",
"     \"Modes of mechanical ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most commonly used ventilator in neonates has been the continuous flow, time-cycled pressure-limited (TCPL) ventilator that has been the standard in the neonatal intensive care unit (NICU) for more than three decades. Adaptions of the TCPL include synchronized and pressure support ventilation, which are commonly employed in the NICU setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pressure-limited ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TCPL ventilator provides a continuous flow of heated and humidified air and delivers a breath that is set by peak inspiratory pressure (PIP) and either the absolute inspiratory time or inspiratory:expiratory time ratio (I:E ratio). The delivered tidal volume is dependent upon the PIP, the lung compliance and resistance, and the tubing resistance. The tidal volume will be larger with an increase in PIP and lung compliance, and decreases with increased lung or tubing resistance. A background level of positive end expiratory pressure (PEEP) is adjusted independently to maintain lung recruitment. The clinician sets the PIP, I:E ratio, respiratory rate, PEEP, and inspired oxygen concentration (FiO2).",
"   </p>",
"   <p>",
"    Arterial oxygen tension (PaO2) generally rises with increases in the FiO2 and mean airway pressure (MAP) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4729/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Mean airway pressure can be adjusted by changes in the I:E ratio, PIP, and PEEP, thereby affecting the PaO2. The level of arterial carbon dioxide tension (PaCO2) is determined by the minute ventilation, which is set by the respiratory rate and PIP.",
"   </p>",
"   <p>",
"    The TCPL ventilator is relatively simple to use and less costly than other ventilators. Thus, until recently, it has been the most commonly used ventilator in the NICU setting. Other advantages of this system include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Spontaneous respiration between ventilator breaths due to the continuous flow of air. Weaning from the ventilator by simply reducing the mandatory ventilator rate is an easy process and allows spontaneous patient breaths to contribute an increasing proportion of the minute ventilation.",
"     </li>",
"     <li>",
"      The ability to control the PIP and MAP. High airway pressure may be a contributor to chronic lung damage (ie, barotrauma).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the TCPL ventilator has the following shortcomings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased work of breathing during spontaneous breathing.",
"     </li>",
"     <li>",
"      Poor synchrony between spontaneous and mandatory breaths. Asynchrony has been associated with deterioration in oxygenation, increases in PCO2, and reduction in tidal volume and minute ventilation [",
"      <a class=\"abstract\" href=\"UTD.htm?4/39/4729/abstract/6\">",
"       6",
"      </a>",
"      ]. In addition, wide fluctuations in arterial pulse pressure during asynchrony may increase the risk of intraventricular hemorrhage.",
"     </li>",
"     <li>",
"      Delivered tidal volume is poorly controlled resulting in breath-to-breath variability. This was illustrated in a study of preterm infants that demonstrated exhaled tidal volume was greater than the targeted volume for 25 percent of the breaths and less than the targeted volume for 36 percent of breaths [",
"      <a class=\"abstract\" href=\"UTD.htm?4/39/4729/abstract/7\">",
"       7",
"      </a>",
"      ]. Delivered tidal volume changes when there are alterations in lung compliance and resistance (which occurs with the administration of surfactant), circuit compressed gas volume, and endotracheal tube (ETT) leak.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Synchronized and patient-triggered ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Synchronized and patient-triggered ventilators are adaptations of the TPLC ventilatory system that address the issue of asynchrony. They combine the features of the TPLC ventilator (ie, continuous flow, pressure limitation, and time cycle), with a flow sensor at the airway opening (ie, endotracheal tube adaptor) that detects changes in airway pressure, airflow, or respiratory movements as an indication of a spontaneous breath. The clinician sets the PIP, I:E ratio, respiratory rate, PEEP, and FIO2.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With synchronized ventilation, when the sensors detect the onset of a spontaneous breath, the ventilator delivers an intermittent positive pressure breath at a fixed rate in synchrony with the infant's inspiratory effort, referred to as synchronized intermittent mandatory ventilation (SIMV). SIMV prevents breathing out of phase with the ventilator (\"fighting the ventilator\"). In some ventilators, SIMV can be supplemented by pressure-support for the infant's spontaneous breaths. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Pressure-support addition to SIMV'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      With patient-triggered ventilation (also referred to as",
"      <span class=\"nowrap\">",
"       Assist/Control",
"      </span>",
"      <span class=\"nowrap\">",
"       [A/C]",
"      </span>",
"      ventilation), a positive pressure breath is delivered with every inspiratory effort. As a result, if the infant has any spontaneous breaths, the ventilator delivers more positive pressure breaths than the set minimum rate, which usually results in a decrease in the PIP needed for adequate gas exchange.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In both types of ventilation, the operator selects a minimal mandatory IMV rate to provide backup ventilation if the patient is apneic.",
"   </p>",
"   <p>",
"    The theoretical benefits of synchronizing the infant's attempt to breathe with the mechanical breath from the ventilator include a lower peak inspiratory pressure (PIP), with potentially less air leak and chronic lung damage, and a reduction in the amount of sedatives administered, thereby shortening the weaning process from the ventilator.",
"   </p>",
"   <p>",
"    Currently available data demonstrate some, but not substantial benefit of synchronized versus nonsynchronized ventilation including fewer periods of low oxygen saturation and less variability in breath-to-breath exhaled tidal volume [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4729/abstract/8-13\">",
"     8-13",
"    </a>",
"    ]. However, synchronized ventilation does not appear to significantly reduce the mortality rate or the incidence of BPD. This was illustrated in a meta-analysis of five studies that included 1729 patients as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4729/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although there was a trend towards an increase in the death rate of infants using the SIMV or patient-triggered ventilator compared to those with conventional IMV, this was not statistically significant (RR: 1.19, 95% CI 0.95 to 1.49).",
"     </li>",
"     <li>",
"      There were no differences in the rates of air leaks, severe intraventricular hemorrhage, bronchopulmonary dysplasia, or extubation failure between the two groups.",
"     </li>",
"     <li>",
"      There was a shorter duration of ventilation in the infants who received synchronized or patient-triggered versus conventional ventilation (weighted mean difference of -35 hours, 95% CI -62 to 7 hours).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the overall outcome of mortality rate and the incidence of BPD did not differ between infants who received synchronized versus nonsynchronized ventilation, experts in the field suggest that synchronization may be useful in a subgroup of preterm infants below 28 weeks of age who are more susceptible to lung injury because of the shorter period of ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4729/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Pressure-support addition to SIMV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pressure-support ventilation (PSV) is a patient-triggered, pressure-limited, flow-cycled mode of ventilation. It delivers inspiratory support to each spontaneous patient breath until the inspiratory flow decreases to a predetermined percentage of its peak value, usually 25 percent. The clinician sets the inspiratory pressure level, inspiratory flow rate, PEEP, FiO2, and a mandatory back up respiratory rate. It may be used alone or combined with SIMV.",
"   </p>",
"   <p>",
"    In this mode of ventilation, flow cycling is used to assist every spontaneous inspiratory effort and terminates ventilator-derived breaths as spontaneous inspiration ends or inflation is completed. As a result, synchrony is improved because the patient modulates the duration of the inspiration. The tidal volume is dependent upon the ventilator settings and patient factors, such as lung compliance and level of consciousness.",
"   </p>",
"   <p>",
"    The work of breathing is inversely proportional to the pressure support level because pressure support counteracts the resistance imposed by the endotracheal tube and ventilator circuit. The inspiratory pressure-support is usually set at 30 to 50 percent of the difference between the PIP and PEEP, but with some ventilators, a minimal pressure support level of 10 cm above PEEP level is necessary to reduce the work of breathing. In addition, a higher inspiratory flow rate shortens the time to reach maximal airway pressure, which decreases the work of breathing. A minimum mandatory ventilator rate is set by the user to provide backup ventilation in case of apnea.",
"   </p>",
"   <p>",
"    There are limited data comparing SIMV with pressure-support to SIMV alone. Small observational studies suggested that the addition of pressure support resulted in an ability to reduce the mandatory ventilator respiratory rate, which led to an overall reduction in mean airway pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4729/abstract/16,17\">",
"     16,17",
"    </a>",
"    ], an overall decrease in respiratory rate, and an increase in minute ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4729/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the single randomized trial of 107 preterm infants (birth weight 500 to 1000 g) that compared SIMV with pressure-support to SIMV alone, infants assigned to SIMV with pressure-support during the first week of life were less likely to require mechanical ventilation at 28 days of life (47 versus 69 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4729/abstract/19\">",
"     19",
"    </a>",
"    ]. However, the mean total days of mechanical ventilation and supplemental oxygen during the first 28 days of life did not differ between the two groups. There were also no differences in mortality rate, or the incidences of sepsis, patent duct arteriosus (PDA), grade III or IV intraventricular hemorrhage (IVH), necrotizing enterocolitis (NEC), or stage III retinopathy of prematurity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Volume-targeted ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have demonstrated that volume distension of the lung, rather than peak airway pressure, induces microvascular lung injury [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4729/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. As discussed previously, pressure-limited ventilation poorly controls the delivered tidal volume, resulting in a wide range of breath-to-breath tidal volumes. In particular, these large variations in delivered volume over time subject the immature lungs of preterm infants to risks of both overdistension and collapse of air spaces.",
"   </p>",
"   <p>",
"    This is particularly problematic following the administration of surfactant, when lung compliance may rapidly change resulting in the delivery of excessive volume with the risk of progressive hypocarbia (risk factor for IVH) or pulmonary air leak due to pulmonary overdistension. As a result, beginning in the late 1990s, research efforts have been directed at controlling tidal volume during neonatal mechanical ventilation, especially in preterm infants [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4729/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the neonate, two modes of volume-targeted ventilation have been generally used [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4729/abstract/1,23\">",
"     1,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Volume-controlled (VC) ventilation &mdash; The clinician presets the tidal volume (generally 4 to 6",
"      <span class=\"nowrap\">",
"       mL/kg),",
"      </span>",
"      the respiratory rate, and an inspiratory time limit. The duration of inflation is dependent upon the time to deliver the set tidal volume. However, the total volume may not be delivered if the preset inspiratory time limit is exceeded. The rate of flow, PIP, and inspiratory time may vary from breath-to-breath.",
"     </li>",
"     <li>",
"      Volume-guarantee ventilation (VG) &mdash; VG ventilation is a form of time-cycled, pressure-limited ventilation. The clinician selects an expiratory tidal volume target, inspiratory time, and a maximum inspiratory pressure limit. A flow sensor is placed at the endotracheal tube, which measures the inspired and expired tidal volume. The PIP varies up to the preset maximum pressure as the ventilator delivers the preset tidal volume. PIP decreases with improvement in lung compliance and increased spontaneous respiratory effort by the infant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several studies have shown that VG combined with either SIMV or patient-triggered pressure-limited ventilation compared to conventional pressure-limited ventilation was associated with the following additional benefits:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Provided effective gas exchange while reducing the number of high volume mechanical breaths [",
"      <a class=\"abstract\" href=\"UTD.htm?4/39/4729/abstract/24\">",
"       24",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Maintained tidal volume closer to the targeted goal and reduced the incidence of hypocapnia (an indicator of overventilation) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/39/4729/abstract/1\">",
"       1",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Decreased PIP of triggered ventilations while maintaining the targeted tidal volume [",
"      <a class=\"abstract\" href=\"UTD.htm?4/39/4729/abstract/25\">",
"       25",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Increasingly, there is evidence that suggests that volume-targeted ventilator strategies may be superior to pressure-limited ventilation in the management of acute respiratory failure in neonates. In a 2010 meta-analysis of twelve trials that included 693 preterm infants, volume-targeted ventilation was associated with a lower rate of the combined outcome of death or bronchopulmonary dysplasia (BPD) compared with pressure-limited ventilation (RR 0.73, 95% CI 0.57-0.93) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4729/abstract/26\">",
"     26",
"    </a>",
"    ]. In addition, volume targeted ventilation was associated with a reduction in the rate of pneumothorax (RR 0.46, 95% CI 0.25-0.84), days of ventilation, hypocarbia (RR 0.56, 95% CI 0.33-0.96), and significant neurologic injury (periventricular leukomalacia or grade 3 or 4 intraventricular hemorrhage), (RR 0.48, 95% CI 0.28-0.84).",
"   </p>",
"   <p>",
"    Although the above results are suggestive that volume-targeted ventilation improves short-term outcome with a reduction in rate of complications associated with mechanical ventilation, further study of this technique in the NICU setting is needed for the following reasons [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4729/abstract/23,27\">",
"     23,27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Studies have been conducted by investigators with expertise in the use of volume-targeted ventilation. In general, these ventilators are more difficult to operate than the TCPL ventilators that have been the standard mode of ventilation for many years. As a result, it is unclear whether these results would be replicated in a wider application of this modality by less experienced clinicians. Care providers will need to be fully train in order to optimally use volume-targeted ventilators in neonates.",
"     </li>",
"     <li>",
"      Several different ventilators and modes of ventilation were used in these studies. In some of them, different ventilators were used for the volume targeted versus pressure limited groups. At present it is not possible to determine which ventilator or mode of ventilation accounted for the reported differences in outcome. It is difficult, therefore, to translate these data into recommendations for clinical practice.",
"     </li>",
"     <li>",
"      There are variations in the delivery of tidal volume, inflation time, and peak pressures amongst the volume-targeted ventilators used in the above studies [",
"      <a class=\"abstract\" href=\"UTD.htm?4/39/4729/abstract/28\">",
"       28",
"      </a>",
"      ]. Also, air leaks around non-cuffed endotracheal tubes make monitoring of expired tidal volume problematic. As a result, if volume-triggered ventilation is used, it remains uncertain what is the optimal tidal volume [",
"      <a class=\"abstract\" href=\"UTD.htm?4/39/4729/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nevertheless, we currently use volume-targeted ventilation for initial management of most neonates with acute lung disease who require mechanical ventilation. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Our approach'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     HIGH FREQUENCY VENTILATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;High frequency ventilation (HFV) delivers small volumes of gas, which are equal to or smaller than anatomic dead space, at an extremely rapid rate (300 to 1500 breaths per minute). Although there are differences in their designs, currently available HF ventilators deliver similar ventilatory output. Each HF ventilator applies continuous distending pressure to maintain lung expansion and superimposes small tidal volumes at a rapid rate.",
"   </p>",
"   <p>",
"    The following three types of HF ventilators are used in neonates:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The high frequency oscillator ventilator (HFOV) delivers small tidal volumes by oscillating air movements produced by the ventilator diaphragm or piston at frequencies of 600 to 900 breaths per minute (10 to 15 Hz), which result in both positive and negative pressure fluctuations and gas mixing. The clinician sets the amplitude and frequency of the pressure wave generated by the ventilator piston or diaphragm, MAP, inspiratory time, and FiO2. Unlike the other two modes of HFV, expiration is an active process with HFOV and \"sigh breaths\" are not utilized. HFOV has been the most extensively studied HFV mode in neonates.",
"     </li>",
"     <li>",
"      The high frequency jet ventilator (HFJV) uses time-cycled pressure-limited, constant gas flow interrupters that are used in parallel with a conventional ventilator, which provides PEEP and intermittent conventional breaths at 2 to 10",
"      <span class=\"nowrap\">",
"       breaths/min",
"      </span>",
"      (referred to as sigh breaths). Sigh breaths are thought to prevent atelectasis. High frequency jet breaths are delivered through a special endotracheal adapter. The clinician sets PIP for both the jet and conventional breaths, PEEP, frequency of jet breaths (usually 420 breaths per minute), the inspiratory jet valve on-time (usually 0.02 seconds), and FiO2. Expiration is passive and is dependent on chest wall and lung recoil.",
"     </li>",
"     <li>",
"      The high frequency flow interrupter (HFFI) is an adaptation of conventional mechanical ventilators that operates similarly to the HFJV. Gas from a high-pressure source is delivered into the standard ventilator circuit and endotracheal tube. High frequency breaths are produced when the flow of gas is interrupted by a valve mechanism. The clinician sets PIP, PEEP, frequency of breaths (usually between 6 and 20 Hz), and FiO2. HFFI has been the least studied HFV mode in neonates and is infrequently used.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although data from animal studies suggested that HFV appeared to reduce lung injury compared to conventional ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4729/abstract/30\">",
"     30",
"    </a>",
"    ], most studies show",
"    <strong>",
"     no",
"    </strong>",
"    significant benefit with any form of HFV compared to conventional ventilation in reducing mortality rate or the incidence of BPD in preterm human infants with respiratory distress syndrome (RDS) as discussed in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H164619\">",
"    <span class=\"h2\">",
"     Elective HFOV versus conventional ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of 10 trials with 3229 patients using individual patient&rsquo;s data demonstrated no difference in the outcome between elective HFOV and conventional ventilation (CV) in the treatment of preterm infants with RDS [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4729/abstract/31\">",
"     31",
"    </a>",
"    ]. The mean gestational age of the included infants was 27.3 &plusmn; 3.8 weeks and mean birthweight was 989 &plusmn; 315 g. About 13 percent of infants had a birth weight that was less than the 10th percentile for gestational age and 56 percent had received antenatal corticosteroids. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In nine trials, there were no differences in the three primary outcomes between the two groups:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Death or bronchopulmonary dysplasia at 36 weeks postmenstrual age (RR 1.0, 95% CI 0.88-1.13).",
"     </li>",
"     <li>",
"      Death or severe neurologic injury defined as grade III or IV intracranial hemorrhage",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cystic periventricular leukomalacia (RR 1.0, 95% CI 0.88-1.13).",
"     </li>",
"     <li>",
"      Death, severe neurologic adverse event, or bronchopulmonary dysplasia at 36 weeks postmenstrual age (RR 0.98, 95% CI 0.91-1.05).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No specific subpopulations based upon sex, gestational age, presence of chorioamnionitis, oxygenation index at trial entry, or antenatal treatment with corticosteroids were identified who benefited from the use of HFOV compared with conventional ventilation. The timing of the first surfactant dose also did not alter primary outcomes between the two groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A meta-analysis of 15 trials with 3585 patients based upon trial data also reported similar findings [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4729/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There were no significant differences between the HFOV and CV groups in mortality rate at 28 to 30 days of life in nine trials (RR 1.09, 95% CI 0.88 to 1.35), at 36 to 37 weeks postmenstrual age (PMA), and at discharge in 13 trials (RR 0.98, 95% CI 0.83 to 1.14).",
"     </li>",
"     <li>",
"      There was no difference in the incidence of chronic lung disease (CLD) defined as oxygen therapy at 28 to 30 days of life in six trials (RR 0.98, 95% CI 0.88 to 1.1). When CLD was defined as oxygen therapy at 36 to 37 weeks PMA, there was a reduction of CLD in the HFOV group of borderline significance in 14 trials (RR 0.89, 95% CI 0.81 to 0.99).",
"     </li>",
"     <li>",
"      There was no difference in the risk of the combined outcome of death or CLD at 28 to 30 days of life in five trials (RR 0.94, 95% CI 0.85 to 1.04). At 36 to 37 weeks PMA, there was a small reduction of the combined outcome of death or CLD in the HFOV group of borderline significance in 13 trials (RR 0.93, 95% CI 0.86 to 1.00).",
"     </li>",
"     <li>",
"      There was variability in the incidence of severe IVH among the 15 trials. Two trials reported that severe IVH, defined as grades III and IV, was higher in the HFOV groups. [",
"      <a class=\"abstract\" href=\"UTD.htm?4/39/4729/abstract/33,34\">",
"       33,34",
"      </a>",
"      ]. However, overall there was no difference in the rate of severe IVH (RR 1.11, 95% CI 0.95 to 1.3) from pooled data from all 15 trials.",
"     </li>",
"     <li>",
"      Although the age and methods of assessment differ among the six studies that evaluated long-term neurodevelopment outcome, in five trials there was no difference in neurodevelopmental status between the two groups. In one trial, the rate of moderate to severe neurodevelopmental outcome (defined as a Bayley psychometric test score of more than one standard deviation below the mean or a neurologic abnormality detected by neurologic examination) was higher in the HFOV group [",
"      <a class=\"abstract\" href=\"UTD.htm?4/39/4729/abstract/33\">",
"       33",
"      </a>",
"      ]. This study had also reported a higher risk of severe IVH in the HFOV group, which was associated with a greater likelihood of abnormal neurodevelopmental outcome [",
"      <a class=\"abstract\" href=\"UTD.htm?4/39/4729/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Follow-up reports of two trials not included in the second meta-analysis presented outcome data. In the first study, there were no differences in neurodevelopmental and pulmonary outcomes at two years of age between the infants who were assigned HFOV versus those who received CV [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4729/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. In the second study, although there was a higher incidence of severe IVH in the HFOV group, the incidence of cerebral palsy was lower in the HFOV group at two years of corrected age (4 versus 17 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4729/abstract/34,37\">",
"     34,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These results suggest there is no additional substantial benefit of elective HFOV that warrants its additional cost over CV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H164716\">",
"    <span class=\"h2\">",
"     Elective HFJV versus conventional ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;HFJV has been less rigorously studied in preterm infants compared to HFOV. Results from two small clinical trials that randomly assigned patients to either HFJV or CV varied as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 73 preterm infants (birth weights between 500 to 2000 g) with RDS, 95 percent of whom received surfactant therapy, there were no differences in the rates of pulmonary air leak, need for oxygenation or ventilation at 36 weeks PMA, total duration of days for supplemental oxygen, and length of stay between the two groups [",
"      <a class=\"abstract\" href=\"UTD.htm?4/39/4729/abstract/38\">",
"       38",
"      </a>",
"      ]. Infants who were assigned HFJV were more likely to have Grade 4 IVH, cystic periventricular leukomalacia",
"      <strong>",
"       or",
"      </strong>",
"      death (17 versus 7 percent).",
"     </li>",
"     <li>",
"      In a multicenter study of 130 preterm infants (birth weights 700 to 1500 g) who received surfactant therapy, there were no differences in the mortality rate, and the incidences of retinopathy of prematurity (ROP), pulmonary air leak, and severe IVH. Infants assigned to HFJV compared to those who received CV were less likely to need oxygen at 36 weeks PMA or at home after discharge.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results suggest that elective HFJV does not offer additional benefits over CV in reducing mortality rate or the incidence of BPD and in fact, based upon the first study, HFJV may be associated with a poorer outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H164741\">",
"    <span class=\"h2\">",
"     Rescue HFV versus conventional ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data from two studies performed in the late 1980s, prior to the general availability of surfactant, demonstrated no added benefit from HFV compared to CV as rescue therapy in preterm infants.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One multicenter trial randomly assigned patients 182 preterm infants (gestational age less than 35 weeks and birth weight greater than 500 g) with pulmonary interstitial emphysema (PIE) or at risk of developing PIE to either HFOV or CV [",
"      <a class=\"abstract\" href=\"UTD.htm?4/39/4729/abstract/39\">",
"       39",
"      </a>",
"      ]. There were no differences in the mortality rate, the need for intermittent positive pressure ventilation at 28 days of age, or the incidences of PIE or gross pulmonary leak (eg, pneumothorax or pneumomediastinum) between the two groups. In patients without PIE at study entry, infants assigned to HFOV compared to those who received CV had a lower risk of developing pulmonary air leak (RR 0.73, 95% CI 0.55 to 0.96). However, the rate of IVH of any grade was greater in the HFOV group (RR 1.77, 95% CI 1.06 to 2.96).",
"     </li>",
"     <li>",
"      In a second study of 144 preterm infants with PIE, patients were initially assigned to either HFJV or CV, but if the criteria for treatment failure were met, crossover to the alternate ventilation mode was permitted [",
"      <a class=\"abstract\" href=\"UTD.htm?4/39/4729/abstract/40\">",
"       40",
"      </a>",
"      ]. Although the overall mortality based upon intention to treat was not different between the two groups (RR 1.07, 95% CI 0.67 to 1.72), mortality up until the point of crossover was lower in the HFJV group. There was also a trend to a reduction in the incidence of BPD in the HFJV group (RR 0.77, 95% CI 0.54 to 1.07).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data are inconclusive regarding the use of rescue HFV, especially as they were conducted prior to the general availability of surfactant therapy. Nevertheless, when infants fail CV with persistent poor gas exchange when positive inspiratory pressure (PIP) is equal to or greater than 30 cm H2O or mean air pressure exceeds 12 cm H2O in infants, HFV offers an alternate mode of ventilation that may provide better ventilation and oxygenation in the neonate with severe respiratory disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     NONINVASIVE MECHANICAL VENTILATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal nasal intermittent positive pressure ventilation (NIPPV) provides noninvasive respiratory support to preterm infants who otherwise would require endotracheal intubation and ventilation. It is an augmentation of continuous positive airway pressure (CPAP), which superimposes inflations set to a peak pressure delivered through nasal prongs or mask [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4729/abstract/15\">",
"     15",
"    </a>",
"    ]. Some devices attempt to synchronize inflations with the infant's spontaneous inspirations.",
"   </p>",
"   <p>",
"    Data are limited in the use of NIPPV and generally are based upon observational or very small clinical trials. As a result, it is uncertain whether the use of NIPPV is beneficial in neonates who require respiratory support and in what settings. However, NIPPV is increasingly being used clinically, especially for postextubation stabilization.",
"   </p>",
"   <p>",
"    NIPPV has been used for the following indications [",
"    <a class=\"abstract\" href=\"UTD.htm?4/39/4729/abstract/15,41\">",
"     15,41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Apnea of prematurity (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/13/43223?source=see_link&amp;anchor=H11#H11\">",
"       \"Management of apnea of prematurity\", section on 'Nasal continuous positive airway pressure'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Following extubation; NIPPV compared to nasal CPAP has been shown to reduce extubation failure in infants who required intubation and ventilation [",
"      <a class=\"abstract\" href=\"UTD.htm?4/39/4729/abstract/41-44\">",
"       41-44",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Primary mode of ventilation in preterm infants with RDS (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/34/43561?source=see_link&amp;anchor=H23056144#H23056144\">",
"       \"Prevention and treatment of respiratory distress syndrome in preterm infants\", section on 'Nasal intermittent positive pressure ventilation'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     OUR APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the currently available data, we do not routinely use high frequency ventilators in treating neonates who require respiratory support because this mode of ventilation does not add any significant benefit over the less costly and easier to operate conventional ventilators.",
"   </p>",
"   <p>",
"    There appears to be no difference in the mortality rate or risk of BPD between synchronized and nonsynchronized pressure-limited ventilation. However, synchronized ventilation may have additional short-term benefits compared to nonsynchronized ventilation, including enhanced oxygenation stability, decreased blood pressure fluctuation, improved patient comfort, and reduced duration of ventilator support. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Synchronized and patient-triggered ventilation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In our institutions, synchronized ventilation (SIMV or",
"    <span class=\"nowrap\">",
"     A/C)",
"    </span>",
"    with volume guarantee using a TCPL ventilator is the initial mode of ventilation in most neonates requiring respiratory support. Target tidal volumes for volume guarantee are 4 to 6",
"    <span class=\"nowrap\">",
"     ml/kg",
"    </span>",
"    with permissive hypercarbia (PCO2 up to 60 mmHg with pH &ge;7.20).",
"   </p>",
"   <p>",
"    Other modes of ventilation are used in selected settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pressure support ventilation (PSV) is generally reserved for older infants with established BPD who require long-term ventilator support or are difficult to wean from SIMV. Limited data suggest that PSV alone or combined with SIMV can maintain adequate gas exchange and augment spontaneous breathing while reducing the work of breathing and need for mandatory ventilator breaths. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Pressure-support addition to SIMV'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      High frequency ventilation is used as rescue therapy when positive inspiratory pressure (PIP) is equal to or greater than 30 cm H2O or mean air pressure exceeds 10 to 12 cm H2O (depending on the infant&rsquo;s weight) in infants treated by conventional ventilation.",
"     </li>",
"     <li>",
"      We do not currently employ nasal intermittent positive pressure ventilation (NIPPV) routinely due to limited available data. We utilize nasal CPAP for management of apnea of prematurity and early, mild RDS.",
"     </li>",
"     <li>",
"      If TCPL SIMV ventilation is used without VG, we monitor expired tidal volume and adjust PIP in attempt to maintain TV in the range of 4 to 6",
"      <span class=\"nowrap\">",
"       mL/kg.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pressure-limited ventilation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Weaning the ventilator in volume-targeted modes involves weaning FiO2 and target tidal volume. Extubation may be considered when the infant exhibits comfortable spontaneous breathing and satisfactory blood gas values with FiO2 &lt;0.4, set tidal volume reduced to 4 to 4.5",
"    <span class=\"nowrap\">",
"     mL/kg,",
"    </span>",
"    and SIMV rate 20 to 25.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/62/8163?source=see_link\">",
"       \"Patient information: What to expect in the NICU (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/44/23233?source=see_link\">",
"       \"Patient information: Persistent pulmonary hypertension in a newborn (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The principal benefits of ventilation are improved gas exchange, decrease work of breathing, and improved ventilation for patients with apnea or respiratory depression. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Background'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately two-thirds of all infants admitted to the neonatal intensive care unit (NICU) require positive pressure ventilation because of apnea, or poor gas exchange with ventilation and perfusion mismatch due to immature lung function, infection, meconium, congenital anomalies, or persistent pulmonary hypertension. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Background'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although mechanical ventilation is life saving and has improved neonatal survival, it may cause chronic lung injury resulting in bronchopulmonary dysplasia (BPD). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18793?source=see_link\">",
"       \"Pathogenesis and clinical features of bronchopulmonary dysplasia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ventilators used in the NICU setting can be divided into conventional and high frequency ventilators. Conventional ventilators are based upon delivery of intermittent mandatory or patient-triggered breaths while continuous air flows through the ventilator circuit. High frequency ventilation (HFV) is based upon delivery of small volume of air (generally equal or less than the anatomic dead space) at an extremely rapid rate (300 to 1500 breaths per minute).",
"     </li>",
"     <li>",
"      Strategies using volume-targeted ventilation or HFV ventilation have been developed in the attempt to reduce neonatal lung damage due to positive pressure ventilation. Limited data suggest improved outcomes using a volume-targeted versus pressure-limited ventilation, especially in preterm infants who are at risk for BPD. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Volume-targeted ventilation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There appears to be no difference in the mortality rate or risk of BPD between synchronized and nonsynchronized pressure-limited ventilation. However, synchronized ventilation may have additional short-term benefits including enhanced oxygenation stability, decreased blood pressure fluctuation, improved patient comfort, and reduced duration of ventilator support. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Synchronized and patient-triggered ventilation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In neonates requiring respiratory support, we suggest the use of volume-target strategy combined with patient-triggered ventilator breaths (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). In our institutions, this is most commonly done using synchronized intermittent ventilation (SIMV) plus volume guarantee (VG), or",
"      <span class=\"nowrap\">",
"       assist/control",
"      </span>",
"      <span class=\"nowrap\">",
"       (A/C)",
"      </span>",
"      plus VG. We allow permissive hypercarbia with PCO2 up to 60 mmHg with pH &ge;7.20. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Our approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other modes of ventilation are reserved for selected settings. These include SIMV and pressure support ventilation for infants with BPD who require long-term ventilator support or who are having difficulty weaning from SIMV pressure-limited ventilation, as well as high frequency ventilation as a rescue therapy when infants fail SIMV pressure-limited ventilation. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Our approach'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Pressure-support addition to SIMV'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'High frequency ventilation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4729/abstract/1\">",
"      McCallion N, Davis PG, Morley CJ. Volume-targeted versus pressure-limited ventilation in the neonate. Cochrane Database Syst Rev 2005; :CD003666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4729/abstract/2\">",
"      Cullen AB, Cooke PH, Driska SP, et al. The impact of mechanical ventilation on immature airway smooth muscle: functional, structural, histological, and molecular correlates. Biol Neonate 2006; 90:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4729/abstract/3\">",
"      Donn SM, Sinha SK. Minimising ventilator induced lung injury in preterm infants. Arch Dis Child Fetal Neonatal Ed 2006; 91:F226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4729/abstract/4\">",
"      Reynolds EO. Effect of alterations in mechanical ventilator settings on pulmonary gas exchange in hyaline membrane disease. Arch Dis Child 1971; 46:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4729/abstract/5\">",
"      Stewart AR, Finer NN, Peters KL. Effects of alterations of inspiratory and expiratory pressures and inspiratory/expiratory ratios on mean airway pressure, blood gases, and intracranial pressure. Pediatrics 1981; 67:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4729/abstract/6\">",
"      Bolivar JM, Gerhardt T, Gonzalez A, et al. Mechanisms for episodes of hypoxemia in preterm infants undergoing mechanical ventilation. J Pediatr 1995; 127:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4729/abstract/7\">",
"      Keszler M, Abubakar K. Volume guarantee: stability of tidal volume and incidence of hypocarbia. Pediatr Pulmonol 2004; 38:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4729/abstract/8\">",
"      Firme SR, McEvoy CT, Alconcel C, et al. Episodes of hypoxemia during synchronized intermittent mandatory ventilation in ventilator-dependent very low birth weight infants. Pediatr Pulmonol 2005; 40:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4729/abstract/9\">",
"      Donn SM, Nicks JJ, Becker MA. Flow-synchronized ventilation of preterm infants with respiratory distress syndrome. J Perinatol 1994; 14:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4729/abstract/10\">",
"      Baumer JH. International randomised controlled trial of patient triggered ventilation in neonatal respiratory distress syndrome. Arch Dis Child Fetal Neonatal Ed 2000; 82:F5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4729/abstract/11\">",
"      Beresford MW, Shaw NJ, Manning D. Randomised controlled trial of patient triggered and conventional fast rate ventilation in neonatal respiratory distress syndrome. Arch Dis Child Fetal Neonatal Ed 2000; 82:F14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4729/abstract/12\">",
"      Greenough A, Dimitriou G, Prendergast M, Milner AD. Synchronized mechanical ventilation for respiratory support in newborn infants. Cochrane Database Syst Rev 2008; :CD000456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4729/abstract/13\">",
"      Cleary JP, Bernstein G, Mannino FL, Heldt GP. Improved oxygenation during synchronized intermittent mandatory ventilation in neonates with respiratory distress syndrome: a randomized, crossover study. J Pediatr 1995; 126:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4729/abstract/14\">",
"      Ramanathan R, Sardesai S. Lung protective ventilatory strategies in very low birth weight infants. J Perinatol 2008; 28 Suppl 1:S41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4729/abstract/15\">",
"      Claure N, Bancalari E. New modes of mechanical ventilation in the preterm newborn: evidence of benefit. Arch Dis Child Fetal Neonatal Ed 2007; 92:F508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4729/abstract/16\">",
"      Osorio W, Claure N, D'Ugard C, et al. Effects of pressure support during an acute reduction of synchronized intermittent mandatory ventilation in preterm infants. J Perinatol 2005; 25:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4729/abstract/17\">",
"      Guthrie SO, Lynn C, Lafleur BJ, et al. A crossover analysis of mandatory minute ventilation compared to synchronized intermittent mandatory ventilation in neonates. J Perinatol 2005; 25:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4729/abstract/18\">",
"      Gupta S, Sinha SK, Donn SM. The effect of two levels of pressure support ventilation on tidal volume delivery and minute ventilation in preterm infants. Arch Dis Child Fetal Neonatal Ed 2009; 94:F80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4729/abstract/19\">",
"      Reyes ZC, Claure N, Tauscher MK, et al. Randomized, controlled trial comparing synchronized intermittent mandatory ventilation and synchronized intermittent mandatory ventilation plus pressure support in preterm infants. Pediatrics 2006; 118:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4729/abstract/20\">",
"      Dreyfuss D, Soler P, Basset G, Saumon G. High inflation pressure pulmonary edema. Respective effects of high airway pressure, high tidal volume, and positive end-expiratory pressure. Am Rev Respir Dis 1988; 137:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4729/abstract/21\">",
"      Hernandez LA, Peevy KJ, Moise AA, Parker JC. Chest wall restriction limits high airway pressure-induced lung injury in young rabbits. J Appl Physiol 1989; 66:2364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4729/abstract/22\">",
"      Dreyfuss D, Saumon G. Ventilator-induced lung injury: lessons from experimental studies. Am J Respir Crit Care Med 1998; 157:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4729/abstract/23\">",
"      Grover A, Field D. Volume-targeted ventilation in the neonate: time to change? Arch Dis Child Fetal Neonatal Ed 2008; 93:F7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4729/abstract/24\">",
"      Herrera CM, Gerhardt T, Claure N, et al. Effects of volume-guaranteed synchronized intermittent mandatory ventilation in preterm infants recovering from respiratory failure. Pediatrics 2002; 110:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4729/abstract/25\">",
"      McCallion N, Lau R, Morley CJ, Dargaville PA. Neonatal volume guarantee ventilation: effects of spontaneous breathing, triggered and untriggered inflations. Arch Dis Child Fetal Neonatal Ed 2008; 93:F36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4729/abstract/26\">",
"      Wheeler K, Klingenberg C, McCallion N, et al. Volume-targeted versus pressure-limited ventilation in the neonate. Cochrane Database Syst Rev 2010; :CD003666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4729/abstract/27\">",
"      Davis PG, Morley CJ. Volume control: a logical solution to volutrauma? J Pediatr 2006; 149:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4729/abstract/28\">",
"      Sharma A, Milner AD, Greenough A. Performance of neonatal ventilators in volume targeted ventilation mode. Acta Paediatr 2007; 96:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4729/abstract/29\">",
"      Lista G, Castoldi F, Fontana P, et al. Lung inflammation in preterm infants with respiratory distress syndrome: effects of ventilation with different tidal volumes. Pediatr Pulmonol 2006; 41:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4729/abstract/30\">",
"      Yoder BA, Siler-Khodr T, Winter VT, Coalson JJ. High-frequency oscillatory ventilation: effects on lung function, mechanics, and airway cytokines in the immature baboon model for neonatal chronic lung disease. Am J Respir Crit Care Med 2000; 162:1867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4729/abstract/31\">",
"      Cools F, Askie LM, Offringa M, et al. Elective high-frequency oscillatory versus conventional ventilation in preterm infants: a systematic review and meta-analysis of individual patients' data. Lancet 2010; 375:2082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4729/abstract/32\">",
"      Henderson-Smart DJ, Cools F, Bhuta T, Offringa M. Elective high frequency oscillatory ventilation versus conventional ventilation for acute pulmonary dysfunction in preterm infants. Cochrane Database Syst Rev 2007; :CD000104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4729/abstract/33\">",
"      High-frequency oscillatory ventilation compared with conventional intermittent mechanical ventilation in the treatment of respiratory failure in preterm infants: neurodevelopmental status at 16 to 24 months of postterm age. The HIFI Study Group. J Pediatr 1990; 117:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4729/abstract/34\">",
"      Moriette G, Paris-Llado J, Walti H, et al. Prospective randomized multicenter comparison of high-frequency oscillatory ventilation and conventional ventilation in preterm infants of less than 30 weeks with respiratory distress syndrome. Pediatrics 2001; 107:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4729/abstract/35\">",
"      Johnson AH, Peacock JL, Greenough A, et al. High-frequency oscillatory ventilation for the prevention of chronic lung disease of prematurity. N Engl J Med 2002; 347:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4729/abstract/36\">",
"      Marlow N, Greenough A, Peacock JL, et al. Randomised trial of high frequency oscillatory ventilation or conventional ventilation in babies of gestational age 28 weeks or less: respiratory and neurological outcomes at 2 years. Arch Dis Child Fetal Neonatal Ed 2006; 91:F320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4729/abstract/37\">",
"      Truffert P, Paris-Llado J, Escande B, et al. Neuromotor outcome at 2 years of very preterm infants who were treated with high-frequency oscillatory ventilation or conventional ventilation for neonatal respiratory distress syndrome. Pediatrics 2007; 119:e860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4729/abstract/38\">",
"      Wiswell TE, Graziani LJ, Kornhauser MS, et al. High-frequency jet ventilation in the early management of respiratory distress syndrome is associated with a greater risk for adverse outcomes. Pediatrics 1996; 98:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4729/abstract/39\">",
"      Randomized study of high-frequency oscillatory ventilation in infants with severe respiratory distress syndrome. HiFO Study Group. J Pediatr 1993; 122:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4729/abstract/40\">",
"      Keszler M, Donn SM, Bucciarelli RL, et al. Multicenter controlled trial comparing high-frequency jet ventilation and conventional mechanical ventilation in newborn infants with pulmonary interstitial emphysema. J Pediatr 1991; 119:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4729/abstract/41\">",
"      Bhandari V. Nasal intermittent positive pressure ventilation in the newborn: review of literature and evidence-based guidelines. J Perinatol 2010; 30:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4729/abstract/42\">",
"      Davis PG, Lemyre B, de Paoli AG. Nasal intermittent positive pressure ventilation (NIPPV) versus nasal continuous positive airway pressure (NCPAP) for preterm neonates after extubation. Cochrane Database Syst Rev 2001; :CD003212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4729/abstract/43\">",
"      De Paoli AG, Davis PG, Lemyre B. Nasal continuous positive airway pressure versus nasal intermittent positive pressure ventilation for preterm neonates: a systematic review and meta-analysis. Acta Paediatr 2003; 92:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/39/4729/abstract/44\">",
"      Khalaf MN, Brodsky N, Hurley J, Bhandari V. A prospective randomized, controlled trial comparing synchronized nasal intermittent positive pressure ventilation versus nasal continuous positive airway pressure as modes of extubation. Pediatrics 2001; 108:13.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5032 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-782CD78CC9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_39_4729=[""].join("\n");
var outline_f4_39_4729=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Indications for ventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Types of ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CONVENTIONAL VENTILATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pressure-limited ventilation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Synchronized and patient-triggered ventilation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Pressure-support addition to SIMV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Volume-targeted ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      HIGH FREQUENCY VENTILATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H164619\">",
"      Elective HFOV versus conventional ventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H164716\">",
"      Elective HFJV versus conventional ventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H164741\">",
"      Rescue HFV versus conventional ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      NONINVASIVE MECHANICAL VENTILATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      OUR APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28026?source=related_link\">",
"      Congenital diaphragmatic hernia in the neonate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14520?source=related_link\">",
"      Incidence and mortality of the premature infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/13/43223?source=related_link\">",
"      Management of apnea of prematurity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43784?source=related_link\">",
"      Modes of mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13336?source=related_link\">",
"      Overview of mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18793?source=related_link\">",
"      Pathogenesis and clinical features of bronchopulmonary dysplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/44/23233?source=related_link\">",
"      Patient information: Persistent pulmonary hypertension in a newborn (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/62/8163?source=related_link\">",
"      Patient information: What to expect in the NICU (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27225?source=related_link\">",
"      Persistent pulmonary hypertension of the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26119?source=related_link\">",
"      Physiologic and pathophysiologic consequences of mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18648?source=related_link\">",
"      Prevention and management of meconium aspiration syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/34/43561?source=related_link\">",
"      Prevention and treatment of respiratory distress syndrome in preterm infants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_39_4730="Grade IV IVH in preterm infant";
var content_f4_39_4730=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F87222&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F87222&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 616px\">",
"   <div class=\"ttl\">",
"    Transcranial ultrasound images of grade IV intraventricular hemorrhage in a preterm infant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 596px; height: 678px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronal (A-C), axial (D), and sagittal (E, F) ultrasound images of a grade IV intraventricular hemorrhage in a preterm infant demonstrate a large amount of blood filling a dilated right lateral ventricle (large white arrow), arising from a hemorrhagic germinal matrix (thick arrow) with parenchymal extension of hemorrhage into the right frontal (short arrow) and parietal (arrowhead) lobe. The left lateral ventricle is normal in size and appearance (dashed arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Joseph Farnam, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_39_4730=[""].join("\n");
var outline_f4_39_4730=null;
var title_f4_39_4731="Grain processing antigens in HP";
var content_f4_39_4731=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52325&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52325&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Hypersensitivity pneumonitides associated with grain and flour processing",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Environmental source",
"       </td>",
"       <td class=\"subtitle1\">",
"        Major causative antigen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Grain measurer's lung",
"       </td>",
"       <td>",
"        Cereal grain (Sporobolomyces)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Grain dust (mixture of dust, silica, fungi, insects, and mites)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Miller's lung (dust-contaminated grain)",
"       </td>",
"       <td>",
"        Sitophilus granarius (ie, wheat weevil)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malt worker's disease (moldy barley)",
"       </td>",
"       <td>",
"        Aspergillus fumigatus, Aspergillus clavatus",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_39_4731=[""].join("\n");
var outline_f4_39_4731=null;
var title_f4_39_4732="Vasodilators in chronic AR";
var content_f4_39_4732=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79823&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79823&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Vasodilator therapy in aortic regurgitation (AR)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class I - There is evidence and/or general agreement that vasodilator therapy is indicated in patients with AR in the following setting:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; For chronic therapy in severe AR associated with symptoms or left ventricular dysfunction when surgery is not recommended due to other cardiac or extracardiac factors.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class IIa - The weight of evidence or opinion is in favor of usefulness of vasodilator therapy in patients with AR in the following setting:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; For short-term hemodynamic improvement in patients with symptoms of severe heart failure and severe left ventricular dysfunction before undergoing aortic valve replacement.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class IIb - The efficacy of vasodilator therapy in patients with AR is less well established in the following setting:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; For chronic therapy in severe asymptomatic AR with left ventricular dilatation but normal left ventricular systolic function.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class III - There is evidence and/or general agreement that vasodilator therapy is not useful and may be harmful in patients with AR in the following settings:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; For chronic therapy in mild to moderate asymptomatic AR with normal left ventricular systolic function.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; For chronic therapy in patients who are otherwise candidates for aortic valve replacement including asymptomatic patients with left ventricular systolic dysfunction and symptomatic patients with either normal left ventricular function or mild to moderate left ventricular systolic dysfunction.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Bonow, RO, Carabello, BA, Chatterjee, K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_39_4732=[""].join("\n");
var outline_f4_39_4732=null;
var title_f4_39_4733="Amyloid mutations";
var content_f4_39_4733=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F85771&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F85771&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Mutations/polymorphisms that have been associated with heritable and acquired forms of amyloidosis, 2012",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Subunit proteins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Subunit proteins",
"       </td>",
"       <td class=\"subtitle2\">",
"        Number of mutations shown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transthyretin (TTR)",
"       </td>",
"       <td class=\"centered\">",
"        &gt;100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prion protein (PrP)",
"       </td>",
"       <td class=\"centered\">",
"        &gt;20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alzheimer precursor protein (APP)",
"       </td>",
"       <td class=\"centered\">",
"        32",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bri2",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lysozyme (Lys)",
"       </td>",
"       <td class=\"centered\">",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Apolipoprotein AI (ApoAI)",
"       </td>",
"       <td class=\"centered\">",
"        19",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Apolipoprotein AII (ApoAII)",
"       </td>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fibrinogen A&alpha;",
"       </td>",
"       <td class=\"centered\">",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gelsolin",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cystatin C",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Keratoepithelin/TGF1B1",
"       </td>",
"       <td class=\"centered\">",
"        &gt;40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beta-2 microglobulin",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Tumor-associated Ca signal transducer 2",
"       </td>",
"       <td class=\"centered\">",
"        21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Polymorphisms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Polymorphisms",
"       </td>",
"       <td class=\"subtitle2\">",
"        Number of mutations shown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SAA1/SAA2",
"       </td>",
"       <td class=\"centered\">",
"        5/2",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Apo E4/E2",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Other",
"       </td>",
"       <td class=\"subtitle2\">",
"        Number of mutations shown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pyrin (MEFV)",
"       </td>",
"       <td class=\"centered\">",
"        &gt;60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cryopyrin (CIAS1)",
"       </td>",
"       <td class=\"centered\">",
"        65",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TRAPS (TNFR1)",
"       </td>",
"       <td class=\"centered\">",
"        &gt;60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mevalonate kinase (MVK)",
"       </td>",
"       <td class=\"centered\">",
"        &gt;75",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Presenilin-1 (PS-1)/presenilin-2 (PS-2)",
"       </td>",
"       <td class=\"centered\">",
"        185/13",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Data obtained from&nbsp;resources&nbsp;listing&nbsp;mutations associated with systemic amyloidosis (",
"    <a href=\"file://www.amyloidosismutations.com\" style=\"FONT-STYLE: italic\" target=\"_blank\">",
"     www.amyloidosismutations.com",
"    </a>",
"    ), autoinflammatory diseases (",
"    <a href=\"file://fmf.igh.cnrs.fr/ISSAID/infevers\" style=\"FONT-STYLE: italic\" target=\"_blank\">",
"     file://fmf.igh.cnrs.fr/ISSAID/infevers",
"    </a>",
"    ), and Alzheimers and related neurodegenerative disorders (",
"    <a href=\"file://www.molgen.ua.ac.be/ADMutations\" style=\"FONT-STYLE: italic\" target=\"_blank\">",
"     www.molgen.ua.ac.be/ADMutations",
"    </a>",
"    ).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter D Gorevic, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_39_4733=[""].join("\n");
var outline_f4_39_4733=null;
var title_f4_39_4734="Retinal hemorrhage etiology";
var content_f4_39_4734=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F81915&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F81915&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of retinal hemorrhage in infants and young children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Condition*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Frequency of retinal hemorrhages",
"       </td>",
"       <td class=\"subtitle1\">",
"        Hemorrhage description",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Abusive head trauma",
"        </strong>",
"       </td>",
"       <td>",
"        50 to 100 percent of cases",
"       </td>",
"       <td>",
"        Numerous, extend to retinal periphery, involve multiple layers of the retina",
"       </td>",
"       <td>",
"        History inconsistent with injuries; commonly associated with subdural hemorrhage, fractures, bruising, and intraabdominal injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Perinatal retinal hemorrhages",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         20 to 30 percent of newborns examined during first 24 hours",
"        </p>",
"        <p>",
"         10 to 15 percent of newborns examined during first 72 hours",
"        </p>",
"       </td>",
"       <td>",
"        May be numerous and extend to retinal periphery; usually intraretinal, but may be preretinal or vitreal",
"       </td>",
"       <td>",
"        <p>",
"         More common in vacuum-assisted deliveries",
"        </p>",
"        <p>",
"         Resolves by 4 to 6 weeks",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Unintentional head injury",
"        </strong>",
"       </td>",
"       <td>",
"        0-10 percent of patients",
"       </td>",
"       <td>",
"        Typically few in number and confined to posterior pole",
"       </td>",
"       <td>",
"        Associated with severe mechanism of injury (eg, motor vehicle crash, fall from great height)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Hematologic conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bleeding disorder (eg, hemophilia, von Willebrand disease, vitamin K deficiency)",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"       <td>",
"        All layers of retina, vitreous",
"       </td>",
"       <td>",
"        Characteristic history of bleeding disorder and abnormal coagulation studies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Leukemia",
"       </td>",
"       <td>",
"        Unknown; most patients have fundoscopic changes at some point in disease",
"       </td>",
"       <td>",
"        Usually at the posterior pole in the deep layers of the retina, but may occur in all layers and in the vitreous",
"       </td>",
"       <td>",
"        Characteristic laboratory features (eg, lymphoblasts on peripheral blood smear)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anemia (juvenile pernicious, iron deficiency, sickle cell)",
"       </td>",
"       <td>",
"        Unknown, more common in adults than children",
"       </td>",
"       <td>",
"        Intraretinal dot, blot, flame, or splinter",
"       </td>",
"       <td>",
"        Anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Metabolic conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Glutaric aciduria type 1",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Few in number and confined to the posterior pole",
"       </td>",
"       <td>",
"        Macrocephaly, characteristic basal ganglia findings, may present with subdural hematomas; absence of bony abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Galactosemia",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Vitreous hemorrhage",
"       </td>",
"       <td>",
"        Failure to thrive, cataracts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cerebral malaria",
"       </td>",
"       <td>",
"        20 to 60 percent of children with severe cerebral malaria",
"       </td>",
"       <td>",
"        Multiple white lesions",
"       </td>",
"       <td>",
"        Travel history; fever, anemia, characteristic blood smear findings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Meningitis",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Various",
"       </td>",
"       <td>",
"        Fever, characteristic cerebrospinal fluid findings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Retinal infection (eg, CMV, HSV, toxoplasmosis, rickettsiae)",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Small, intraretinal at areas of retinal necrosis; may span all layers of necrotic retina",
"       </td>",
"       <td>",
"        Systemic signs of infection may be present; immunodeficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Endocarditis",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        White-centered oval hemorrhages",
"       </td>",
"       <td>",
"        Other characteristic features (eg, cardiac murmur, fever, splinter hemorrhages in the nail beds, Janeway lesions)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Primary retinal disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Retinopathy of prematurity",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Small, usually intraretinal on the surface of the neovascular ridge; may extend to the vitreous",
"       </td>",
"       <td>",
"        History of prematurity; retinal neovascularization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Coats disease",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Usually intraretinal but may extend to vitreous",
"       </td>",
"       <td>",
"        Usually unilateral; subretinal exudate; telangiectatic vessels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Persistent fetal vasculature",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        May present with vitreous hemorrhage",
"       </td>",
"       <td>",
"        Usually unilateral; may be associated with mild microphthalmos; intralenticular hemorrhage; retrolental membrane",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intracranial hemorrhage",
"       </td>",
"       <td>",
"        Rare in absence of abusive head injury",
"       </td>",
"       <td>",
"        May be extensive",
"       </td>",
"       <td>",
"        Characteristic neuroradiographic features (eg, aneurysm, arterio-venous malformation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Chest compression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cardiopulmonary resuscitation",
"       </td>",
"       <td>",
"        Rare if ever",
"       </td>",
"       <td>",
"        Few in number, small in size",
"       </td>",
"       <td>",
"        History of cardiopulmonary resuscitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Thoracic crush injury (Purtscher syndrome)",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        Superficial; white retinal patches",
"       </td>",
"       <td>",
"        History of thoracic injury",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CMV: cytomegalovirus; HSV: herpes simplex virus.",
"     <br>",
"      * The presence of an underlying condition does not exclude the possibility of abusive head trauma.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     This appendix is modified from an article entitled, \"A 12-Year Ophthalmologic Experience with the Shaken Baby Syndrome at a Regional Children's Hospital\" in the Trans Am Ophthalmol Soc 1999; 97:545-581 and republished with permission of the American Ophthalmological Society.",
"     <br>",
"      Additional data from: Aryan HE, Ghosheh FR, Jandial R, Levy ML. Retinal hemorrhage and pediatric brain injury: etiology and review of the literature. J Clin Neurosci 2005; 12:624 and Kaur B, Taylor D. Fundus hemorrhages in infancy. Surv Ophthalmol 1992; 37:1.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_39_4734=[""].join("\n");
var outline_f4_39_4734=null;
var title_f4_39_4735="Monoclonal pattern immunofixation";
var content_f4_39_4735=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F55916&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F55916&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Monoclonal gammopathy on immunofixation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 307px; height: 387px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure shows the serum protein electrophoretic pattern (SPEP) and immunofixation pattern of a single serum sample with antisera to heavy chain determinants of IgG, IgA, and IgM, and to kappa and lambda light chains. It shows a discrete band on SPEP (red asterisk) and a band with similar mobility reacting only with the antisera to IgG (blue asterisk) and the kappa light chain (black asterisk), indicative of an IgG kappa monoclonal protein.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kyle RA, Rajkumar SV. Plasma cell disorders. In: Cecil textbook of medicine, 22nd ed, Goldman L, Ausiello DA (Eds), WB Saunders, Philadelphia 2004. p.1184. Copyright &copy; 2004 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_39_4735=[""].join("\n");
var outline_f4_39_4735=null;
